Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Cerus Corporation (CERS)
USD3.14
+0.07 (+2.12%)
US NASDAQ Healthcare Medical - Devices
Address
1220 Concord Avenue 94520
Concord, CA, US
Concord, CA, US
CEO
William Greenman
Website
cerus.com
IPO
1997-01-31
CIK 1020214 ISIN US1570851014
Description
Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma. It also offers a dedicated INTERCEPT Blood System for the inactivation of harmful agents in red blood cell components. Furthermore, Cerus markets an INTERCEPT Blood System for Cryoprecipitation, which leverages its plasma technology to produce two key pathogen-reduced blood products: a cryoprecipitated fibrinogen complex for treating and controlling bleeding, particularly massive hemorrhages stemming from fibrinogen deficiency, and pathogen-reduced, cryoprecipitate-reduced plasma. Cerus distributes these platelet and plasma systems globally through a combination of its direct sales force and an extensive network of distributors, reaching markets in North America, Europe, the Commonwealth of Independent States, the Middle East, and Latin America. Established in 1991, Cerus Corporation maintains its corporate headquarters in Concord, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD3.14
+0.07 (+2.12%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
3M
Beta
1.77
Float Shares
189.07M
Free Float %
94.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.19% | -2.30% | +32.81% | +13.84% | +59.38% | +23.79% | +94.66% | +37.10% | -54.05% | -51.98% | -78.97% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (10 ratings, all time)
Buy
Price Targets & DCF
Current price
3.14
Low
4.00
+27.6%
Consensus
4.00
+27.6%
Median
4.00
+27.6%
High
4.00
+27.6%
DCF (Levered)
5.73
+82.7%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
67% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
4.00
+27.6%
|
| Last Quarter | 1 |
4.00
+27.6%
|
| Last Year | 1 |
4.00
+27.6%
|
| All Time | 4 |
4.00
+27.6%
|
Quality scores
Altman Z-Score
-3.70
Distress
Piotroski F-Score
4 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
5 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Devices: +11.2%+14.4% ★ Q1'26: +38.5% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+25.5% Q1'26: +75.7% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%-25.2% Q1'26: -5.5% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%-17.6% Q1'26: -0.6% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%-46.0% Q1'26: -1.7% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+3.3% Q1'26: +3.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-2.82× Q1'26: 261.72× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2008 actual |
Dec 2009 actual |
Dec 2011 actual |
Dec 2012 actual |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 2 EPS Ana. |
Dec 2027 3 Rev. Ana. 2 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
16.51M
est: 19.74M (-16.4%)
|
17.98M
est: 14.94M (+20.4%)
|
33.04M
est: 36.45M (-9.3%)
|
36.70M
est: 66.06M (-44.5%)
|
39.66M
est: 29.57M (+34.1%)
|
36.50M
est: 41.48M (-12.0%)
|
34.22M
est: 34.27M (-0.1%)
|
37.18M
est: 38.64M (-3.8%)
|
43.57M
est: 51.73M (-15.8%)
|
60.91M
est: 75.58M (-19.4%)
|
74.65M
est: 92.59M (-19.4%)
|
91.92M
est: 91.90M (+0.0%)
|
130.86M
est: 149.11M (-12.2%)
|
162.05M
est: 186.16M (-13.0%)
|
156.37M
est: 169.98M (-8.0%)
|
180.27M
est: 198.96M (-9.4%)
|
206.13M
est: 231.03M (-10.8%)
|
252.78M
243.64M – 270.55M
+9.4% YoY
|
274.17M
266.43M – 287.00M
+8.5% YoY
|
312.00M
298.50M – 325.50M
+13.8% YoY
|
| EBITDA |
-28.53M
est: -30.67M (+7.0%)
|
-22.92M
est: -17.89M (-28.1%)
|
-15.10M
est: -11.57M (-30.5%)
|
-14.38M
est: -16.45M (+12.6%)
|
-42.04M
est: -42.11M (+0.2%)
|
-36.55M
est: -31.43M (-16.3%)
|
-56.14M
est: -9.19M (-510.7%)
|
-58.47M
est: -10.36M (-464.1%)
|
-51.87M
est: -13.88M (-273.8%)
|
-51.88M
est: -51.39M (-1.0%)
|
-64.61M
est: -52.84M (-22.3%)
|
-51.37M
est: -57.56M (+10.8%)
|
-45.99M
est: -51.25M (+10.3%)
|
-33.52M
est: -45.35M (+26.1%)
|
-26.34M
est: 9.88M (-366.5%)
|
-10.02M
est: 11.57M (-186.7%)
|
-34.35M
est: 13.43M (-355.7%)
|
14.69M
14.16M – 15.73M
+9.4% YoY
|
15.94M
15.49M – 16.68M
+8.5% YoY
|
18.14M
17.35M – 18.92M
+13.8% YoY
|
| EBIT |
-29.17M
est: -33.41M (+12.7%)
|
-24.13M
est: -18.33M (-31.6%)
|
-15.88M
est: -14.03M (-13.1%)
|
-15.12M
est: -21.73M (+30.4%)
|
-42.79M
est: -28.08M (-52.4%)
|
-37.96M
est: -48.84M (+22.3%)
|
-57.83M
est: -10.00M (-478.4%)
|
-60.29M
est: -11.27M (-434.7%)
|
-53.68M
est: -15.10M (-255.6%)
|
-53.33M
est: -54.48M (+2.1%)
|
-67.02M
est: -55.89M (-19.9%)
|
-55.83M
est: -63.79M (+12.5%)
|
-49.13M
est: -54.50M (+9.8%)
|
-36.51M
est: -47.26M (+22.8%)
|
-28.94M
est: 10.49M (-375.9%)
|
-11.88M
est: 12.28M (-196.8%)
|
-36.35M
est: 14.26M (-355.0%)
|
15.60M
15.03M – 16.69M
+9.4% YoY
|
16.92M
16.44M – 17.71M
+8.5% YoY
|
19.25M
18.42M – 20.08M
+13.8% YoY
|
| Net Income |
-29.18M
est: -31.38M (+7.0%)
|
-24.14M
est: -18.63M (-29.6%)
|
-16.98M
est: -13.37M (-27.0%)
|
-15.92M
est: -18.24M (+12.8%)
|
-43.34M
est: -43.32M (0.0%)
|
-38.57M
est: -33.92M (-13.7%)
|
-55.87M
est: -117.20M (+52.3%)
|
-62.91M
est: -117.01M (+46.2%)
|
-60.59M
est: -106.68M (+43.2%)
|
-57.56M
est: -57.04M (-0.9%)
|
-71.24M
est: -59.89M (-19.0%)
|
-59.86M
est: -65.39M (+8.5%)
|
-54.37M
est: -61.12M (+11.0%)
|
-42.78M
est: -57.38M (+25.4%)
|
-37.49M
est: -25.58M (-46.6%)
|
-20.92M
est: -23.12M (+9.5%)
|
-15.63M
est: -9.55M (-63.6%)
|
-6.24M
-6.83M – -6.09M
+34.7% YoY
|
-646.0K
-683.2K – -608.8K
+89.6% YoY
|
19.00M
18.27M – 20.50M
+3,041.2% YoY
|
| SGA |
27.16M
est: 10.93M (+148.5%)
|
21.87M
est: 8.27M (+164.4%)
|
23.05M
est: 21.55M (+7.0%)
|
25.67M
est: 32.82M (-21.8%)
|
29.97M
est: 28.82M (+4.0%)
|
37.79M
est: 22.97M (+64.5%)
|
45.99M
est: 18.97M (+142.4%)
|
48.75M
est: 21.39M (+127.9%)
|
52.41M
est: 28.64M (+83.0%)
|
56.84M
est: 56.54M (+0.5%)
|
66.21M
est: 55.85M (+18.5%)
|
67.02M
est: 73.20M (-8.5%)
|
81.29M
est: 95.49M (-14.9%)
|
83.34M
est: 112.85M (-26.2%)
|
75.52M
est: 82.68M (-8.7%)
|
75.89M
est: 96.77M (-21.6%)
|
80.91M
est: 112.37M (-28.0%)
|
122.95M
118.50M – 131.59M
+9.4% YoY
|
133.35M
129.59M – 139.59M
+8.5% YoY
|
151.75M
145.18M – 158.32M
+13.8% YoY
|
| EPS |
-0.90
est: -1.13 (+20.4%)
|
-0.69
est: -0.45 (-53.3%)
|
-0.35
est: -0.36 (+1.4%)
|
-0.29
est: -0.41 (+28.4%)
|
-0.64
est: -0.34 (-91.0%)
|
-0.52
est: -0.59 (+11.9%)
|
-0.58
est: -0.64 (+8.7%)
|
-0.62
est: -0.63 (+2.2%)
|
-0.56
est: -0.58 (+3.1%)
|
-0.44
est: -0.43 (-3.3%)
|
-0.51
est: -0.51 (-0.7%)
|
-0.37
est: -0.37 (-0.8%)
|
-0.32
est: -0.35 (+7.2%)
|
-0.24
est: -0.22 (-10.6%)
|
-0.21
est: -0.13 (-59.1%)
|
-0.11
est: -0.12 (+9.3%)
|
-0.08
est: -0.08 (-2.5%)
|
-0.03
-0.04 – -0.03
+58.3% YoY
|
0.00
0.00 – 0.00
+90.0% YoY
|
0.10
0.10 – 0.11
+3,100.3% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-01 | BTIG | Neutral | Buy | Upgrade |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-08 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-07 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-06 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-05 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-04 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-01 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
3.76M
OE per share TTM
0.02
Owner's Yield
0.77%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
15.9%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
23
Total invested
12.65M
Insider transactions (90d)
0
Beneficial owners (>5%)
16
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ARK Investment Management LLC | 15.76M | 9.15% | 14.35M | 517.6K | 15.76M | — | IA | Delaware, United States | 2022-02-09 | ↗ |
| 2 | Baker Bros. Advisors LP | 13.71M | 8.20% | 13.71M | — | 13.71M | — | IA, PN | Delaware | 2021-02-16 | ↗ |
| 3 | Felix J. Baker | 13.57M | 14.00% | 13.57M | — | 13.57M | — | HC | United States | 2016-02-16 | ↗ |
| 4 | Julian C. Baker | 13.57M | 14.00% | 13.57M | — | 13.57M | — | HC | United States | 2016-02-16 | ↗ |
| 5 | Baker Bros. Advisors (GP) LLC | 13.55M | 14.00% | 13.55M | — | 13.55M | — | HC, OO | Delaware | 2016-02-16 | ↗ |
| 6 | (1) BlackRock, Inc. | 12.21M | 7.10% | 11.85M | — | 12.21M | — | HC | Delaware | 2022-02-01 | ↗ |
| 7 | Nikko Asset Management Americas, Inc. | 11.53M | 6.69% | — | 9.71M | — | 11.53M | IA | USA | 2022-02-14 | ↗ |
| 8 | Nikko Asset Management Co., Ltd. (“NAM”) | 11.53M | 6.69% | — | 11.53M | — | 11.53M | FI, IA, HC | Japan | 2022-02-04 | ↗ |
| 9 | Sumitomo Mitsui Trust Holdings, Inc. (“SMTH”) | 11.53M | 6.69% | — | 11.53M | — | 11.53M | FI, HC | Japan | 2022-02-04 | ↗ |
| 10 | PRIMECAP Management Company 95-3868081 | 11.30M | 7.95% | 11.30M | — | 11.30M | — | IA | 177 E. Colorado Blvd., 11th Floor, Pasadena, CA 91105 | 2020-02-12 | ↗ |
| 11 | PRIMECAP Management Company | 9.72M | 5.64% | 9.72M | — | 9.72M | — | IA | 177 E. Colorado Blvd., 11th Floor, Pasadena, CA 91105 | 2022-02-10 | ↗ |
| 12 | The Vanguard Group - 23-1945930 | 8.82M | 5.12% | — | 316.6K | 8.37M | 449.5K | IA | Pennsylvania | 2022-02-09 | ↗ |
| 13 | ELK CREEK PARTNERS, LLC | 6.55M | 5.74% | 3.91M | — | 6.55M | — | IA | DELAWARE | 2018-02-13 | ↗ |
| 14 | Wells Fargo & Company | 5.03M | 5.18% | 26.1K | 3.02M | 26.1K | — | HC | Delaware | 2016-01-29 | ↗ |
| 15 | NAME OF REPORTING | 2.64M | 3.37% | — | 2.64M | — | 2.64M | IA | Delaware | 2015-02-17 | ↗ |
| 16 | 27-5463196 | 10.00 | 12.00% | — | — | — | — | IA | Delaware | 2020-01-23 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
23
-139 vs prev Q
New positions
3
Closed positions
138
Increased
7
Reduced
8
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | BLACKROCK, INC. | 21.92M +938.7K (+4.5%) | 45.15M +11.8M (+35.4%) | 11.43% +0.459 pp | 0.00% +0.000 pp | USD1.66 +24.1% | 6 qtrs — |
| 2 | ARK INVESTMENT MANAGEMENT LLC | 18.20M -650.0K (-3.4%) | 37.49M +7.5M (+25.1%) | 9.49% -0.366 pp | 0.25% +0.070 pp | USD4.28 -51.9% | 37 qtrs — |
| 3 | VANGUARD GROUP INC | 11.16M +379.1K (+3.5%) | 23.00M +5.8M (+34.1%) | 5.82% +0.182 pp | 0.00% +0.000 pp | USD8.35 -75.3% | 84 qtrs — |
| 4 | BAKER BROS. ADVISORS LP | 10.01M +— (+0.0%) | 20.62M +4.7M (+29.6%) | 5.22% -0.014 pp | 0.12% +0.006 pp | USD4.04 -49.0% | 54 qtrs — |
| 5 | WASATCH ADVISORS LP | 5.46M -76.6K (-1.4%) | 11.25M +2.4M (+27.8%) | 2.85% -0.048 pp | 0.07% +0.020 pp | USD4.11 -49.9% | 21 qtrs — |
| 6 | SUMITOMO MITSUI TRUST HOLDINGS, INC. | 4.71M -975.2K (-17.2%) | 9.70M +663.1K (+7.3%) | 2.46% -0.517 pp | 0.01% +0.001 pp | USD5.10 -59.6% | 28 qtrs — |
| 7 | NIKKO ASSET MANAGEMENT AMERICAS, INC. | 4.71M -975.2K (-17.2%) | 9.66M +616.0K (+6.8%) | 2.46% -0.517 pp | 0.11% +0.024 pp | USD5.08 -59.4% | 30 qtrs — |
| 8 | SILVERCREST ASSET MANAGEMENT GROUP LLC | 4.69M +562.1K (+13.6%) | 9.65M +3.1M (+47.2%) | 2.44% +0.287 pp | 0.07% +0.023 pp | USD3.21 -35.8% | 24 qtrs — |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 4.49M -32.8K (-0.7%) | 9.25M +2.1M (+28.6%) | 2.34% -0.024 pp | 0.00% +0.000 pp | USD4.24 -51.4% | 78 qtrs — |
| 10 | SOLEUS CAPITAL MANAGEMENT, L.P. | 4.00M +4.0M (+100.0%) | 8.24M +8.2M (+100.0%) | 2.09% +2.085 pp | 0.30% +0.304 pp | USD2.06 +0.0% | 1 qtrs NEW |
| 11 | SENVEST MANAGEMENT, LLC | 3.97M +— (+0.0%) | 8.17M +1.9M (+29.6%) | 2.07% -0.006 pp | 0.25% +0.051 pp | USD3.96 -48.0% | 21 qtrs — |
| 12 | D. E. SHAW & CO., INC. | 3.87M +54.3K (+1.4%) | 7.98M +1.9M (+31.4%) | 2.02% +0.023 pp | 0.00% +0.001 pp | USD3.97 -48.1% | 37 qtrs — |
| 13 | STATE STREET CORP | 3.84M -15.6K (-0.4%) | 7.92M +1.8M (+29.0%) | 2.00% -0.014 pp | 0.00% +0.000 pp | USD4.57 -54.9% | 51 qtrs — |
| 14 | ACADIAN ASSET MANAGEMENT LLC | 3.28M +386.4K (+13.4%) | 6.75M +2.2M (+46.8%) | 1.71% +0.197 pp | 0.01% +0.003 pp | USD1.56 +32.1% | 9 qtrs — |
| 15 | SILVERARC CAPITAL MANAGEMENT, LLC | 2.81M +98.6K (+3.6%) | 5.80M +1.5M (+34.3%) | 1.47% +0.048 pp | 0.81% +0.223 pp | USD3.31 -37.8% | 19 qtrs — |
| 16 | IEQ CAPITAL, LLC | 2.42M +25.8K (+1.1%) | 4.99M +1.2M (+31.0%) | 1.26% +0.010 pp | 0.01% +0.003 pp | USD1.76 +17.0% | 8 qtrs — |
| 17 | GOLDMAN SACHS GROUP INC | 2.41M -40.3K (-1.6%) | 4.96M +1.1M (+27.4%) | 1.26% -0.025 pp | 0.00% +0.000 pp | USD2.11 -2.4% | 64 qtrs — |
| 18 | AQR CAPITAL MANAGEMENT LLC | 2.00M -450.8K (-18.4%) | 4.13M +224.7K (+5.8%) | 1.04% -0.239 pp | 0.00% 0.000 pp | USD1.45 +42.1% | 16 qtrs — |
| 19 | MORGAN STANLEY | 1.94M +133.8K (+7.4%) | 4.00M +1.1M (+39.2%) | 1.01% +0.067 pp | 0.00% +0.000 pp | USD2.41 -14.5% | 51 qtrs — |
| 20 | TWO SIGMA INVESTMENTS, LP | 1.86M +712.7K (+62.3%) | 3.83M +2.0M (+110.2%) | 0.97% +0.370 pp | 0.01% +0.003 pp | USD1.74 +18.4% | 10 qtrs — |
| 21 | ASSENAGON ASSET MANAGEMENT S.A. | 1.68M +92.6K (+5.8%) | 3.45M +935.0K (+37.1%) | 0.87% +0.046 pp | 0.00% +0.001 pp | USD1.95 +5.6% | 19 qtrs — |
| 22 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.67M -99.3K (-5.6%) | 3.43M +625.6K (+22.3%) | 0.87% -0.054 pp | 0.00% +0.000 pp | USD4.29 -52.0% | 57 qtrs — |
| 23 | NORTHERN TRUST CORP | 1.45M -90.5K (-5.9%) | 2.98M +536.2K (+21.9%) | 0.75% -0.049 pp | 0.00% +0.000 pp | USD4.93 -58.2% | 51 qtrs — |
| 24 | TWO SIGMA ADVISERS, LP | 1.40M +423.9K (+43.5%) | 2.88M +1.3M (+85.9%) | 0.73% +0.220 pp | 0.01% +0.003 pp | USD1.67 +23.4% | 10 qtrs — |
| 25 | VOYA INVESTMENT MANAGEMENT LLC | 1.19M -330.2K (-21.7%) | 2.46M +36.4K (+1.5%) | 0.62% -0.174 pp | 0.00% +0.000 pp | USD3.48 -40.8% | 51 qtrs — |
| 26 | BANK OF AMERICA CORP /DE/ | 1.18M +78.1K (+7.1%) | 2.43M +678.3K (+38.7%) | 0.61% +0.039 pp | 0.00% +0.000 pp | USD1.45 +42.1% | 52 qtrs — |
| 27 | UBS GROUP AG | 1.14M +793.2K (+227.1%) | 2.35M +1.8M (+323.8%) | 0.60% +0.413 pp | 0.00% +0.000 pp | USD2.01 +2.5% | 45 qtrs — |
| 28 | FMR LLC | 1.03M +203.1K (+24.5%) | 2.13M +808.6K (+61.3%) | 0.54% +0.105 pp | 0.00% +0.000 pp | USD2.99 -31.1% | 16 qtrs — |
| 29 | KOTLER KEVIN | 1.01M +1.0M (+100.0%) | 2.08M +2.1M (+100.0%) | 0.53% +0.527 pp | 0.49% +0.488 pp | USD2.06 +0.0% | 1 qtrs NEW |
| 30 | MILLENNIUM MANAGEMENT LLC | 967.7K -2.5M (-72.1%) | 1.99M -3.5M (-63.9%) | 0.50% -1.310 pp | 0.00% -0.002 pp | USD1.83 +12.6% | 25 qtrs — |
| 31 | BARCLAYS PLC | 890.7K -684.3K (-43.4%) | 1.83M -905.7K (-33.0%) | 0.46% -0.359 pp | 0.00% 0.000 pp | USD2.39 -13.8% | 51 qtrs — |
| 32 | NUVEEN, LLC | 840.5K +69.2K (+9.0%) | 1.73M +505.0K (+41.2%) | 0.44% +0.035 pp | 0.00% +0.000 pp | USD1.54 +33.8% | 4 qtrs — |
| 33 | PRIMECAP MANAGEMENT CO/CA/ | 794.5K -305.5K (-27.8%) | 1.64M -112.3K (-6.4%) | 0.41% -0.161 pp | 0.00% 0.000 pp | USD4.61 -55.3% | 44 qtrs — |
| 34 | IQ EQ FUND MANAGEMENT (IRELAND) LTD | 746.1K +146.3K (+24.4%) | 1.54M +583.3K (+61.2%) | 0.39% +0.075 pp | 0.11% +0.041 pp | USD1.62 +27.2% | 7 qtrs — |
| 35 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 653.2K +378.5K (+137.7%) | 1.35M +908.7K (+208.0%) | 0.34% +0.197 pp | 0.00% +0.002 pp | USD1.88 +9.6% | 6 qtrs — |
| 36 | ALGERT GLOBAL LLC | 553.8K +44.2K (+8.7%) | 1.14M +331.0K (+40.9%) | 0.29% +0.022 pp | 0.02% +0.004 pp | USD1.64 +25.6% | 17 qtrs — |
| 37 | GLOBEFLEX CAPITAL L P | 522.1K +522.1K (+100.0%) | 1.08M +1.1M (+100.0%) | 0.27% +0.272 pp | 0.16% +0.165 pp | USD2.06 +0.0% | 1 qtrs NEW |
| 38 | BANK OF NEW YORK MELLON CORP | 502.1K -23.2K (-4.4%) | 1.03M +199.1K (+23.8%) | 0.26% -0.013 pp | 0.00% +0.000 pp | USD4.13 -50.1% | 66 qtrs — |
| 39 | RENAISSANCE TECHNOLOGIES LLC | 498.0K -341.5K (-40.7%) | 1.03M -308.9K (-23.1%) | 0.26% -0.179 pp | 0.00% 0.000 pp | USD1.75 +17.7% | 21 qtrs — |
| 40 | TOPLINE CAPITAL MANAGEMENT, LLC | 411.0K +411.0K (+100.0%) | 846.6K +846.6K (+100.0%) | 0.21% +0.214 pp | 0.08% +0.077 pp | USD2.06 +0.0% | 1 qtrs NEW |
| 41 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 369.3K +199.3K (+117.2%) | 760.8K +490.5K (+181.4%) | 0.19% +0.104 pp | 0.00% +0.000 pp | USD1.96 +5.1% | 51 qtrs — |
| 42 | AMERIPRISE FINANCIAL INC | 347.0K +347.0K (+100.0%) | 714.8K +714.8K (+100.0%) | 0.18% +0.181 pp | 0.00% +0.000 pp | USD2.06 +0.0% | 15 qtrs — |
| 43 | STIFEL FINANCIAL CORP | 324.2K +2.9K (+0.9%) | 667.8K +156.9K (+30.7%) | 0.17% +0.001 pp | 0.00% +0.000 pp | USD3.18 -35.2% | 22 qtrs — |
| 44 | INVESCO LTD. | 309.2K +69.1K (+28.8%) | 636.9K +255.2K (+66.8%) | 0.16% +0.036 pp | 0.00% +0.000 pp | USD2.56 -19.5% | 23 qtrs — |
| 45 | SEPIO CAPITAL, LP | 295.5K +— (+0.0%) | 608.7K +138.9K (+29.6%) | 0.15% 0.000 pp | 0.03% +0.006 pp | USD1.81 +13.8% | 29 qtrs — |
| 46 | VOLEON CAPITAL MANAGEMENT LP | 291.8K +251.1K (+617.5%) | 601.0K +536.4K (+829.5%) | 0.15% +0.131 pp | 0.01% +0.011 pp | USD1.99 +3.5% | 2 qtrs — |
| 47 | LAZARD ASSET MANAGEMENT LLC | 273.6K -204.2K (-42.7%) | 563.5K -196.2K (-25.8%) | 0.14% -0.107 pp | 0.00% 0.000 pp | USD1.60 +28.8% | 7 qtrs — |
| 48 | ROUND ROCK ADVISORS, LLC | 264.7K +264.7K (+100.0%) | 545.3K +545.3K (+100.0%) | 0.14% +0.138 pp | 0.08% +0.082 pp | USD2.06 +0.0% | 1 qtrs NEW |
| 49 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 256.0K +256.0K (+100.0%) | 527.3K +527.3K (+100.0%) | 0.13% +0.133 pp | 0.00% +0.000 pp | USD2.06 +0.0% | 1 qtrs NEW |
| 50 | RAYMOND JAMES FINANCIAL INC | 255.5K +5.4K (+2.1%) | 526.4K +128.7K (+32.3%) | 0.13% +0.002 pp | 0.00% +0.000 pp | USD1.55 +32.9% | 5 qtrs — |
| 51 | JANE STREET GROUP, LLC | 253.6K -160.7K (-38.8%) | 522.4K -136.3K (-20.7%) | 0.13% -0.084 pp | 0.00% +0.000 pp | USD1.68 +22.6% | 24 qtrs — |
| 52 | XTX TOPCO LTD | 253.2K -34.2K (-11.9%) | 521.7K +64.7K (+14.2%) | 0.13% -0.018 pp | 0.01% -0.010 pp | USD1.62 +27.2% | 16 qtrs — |
| 53 | LOS ANGELES CAPITAL MANAGEMENT LLC | 366.0K -1.4K (-0.4%) | 512.4K -71.8K (-12.3%) | 0.19% -0.001 pp | 0.00% 0.000 pp | USD2.29 -10.0% | 18 qtrs — |
| 54 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 235.0K +— (+0.0%) | 484.1K +110.5K (+29.6%) | 0.12% 0.000 pp | 0.01% +0.002 pp | USD1.47 +40.1% | 3 qtrs — |
| 55 | RHUMBLINE ADVISERS | 229.4K -40.2K (-14.9%) | 472.5K +44.0K (+10.3%) | 0.12% -0.021 pp | 0.00% +0.000 pp | USD4.33 -52.4% | 52 qtrs — |
| 56 | WELLS FARGO & COMPANY/MN | 228.5K +87.1K (+61.6%) | 470.6K +245.8K (+109.3%) | 0.12% +0.045 pp | 0.00% +0.000 pp | USD2.34 -12.0% | 57 qtrs — |
| 57 | ALLIANCEBERNSTEIN L.P. | 220.1K -11.6K (-5.0%) | 453.5K +85.0K (+23.1%) | 0.11% -0.006 pp | 0.00% +0.000 pp | USD4.72 -56.4% | 61 qtrs — |
| 58 | HSBC HOLDINGS PLC | 203.9K +102.1K (+100.3%) | 421.1K +265.8K (+171.2%) | 0.11% +0.053 pp | 0.00% +0.000 pp | USD2.74 -24.8% | 25 qtrs — |
| 59 | JPMORGAN CHASE & CO | 168.3K +91.1K (+118.1%) | 346.6K +224.0K (+182.6%) | 0.09% +0.047 pp | 0.00% +0.000 pp | USD2.36 -12.7% | 36 qtrs — |
| 60 | FRANKLIN RESOURCES INC | 149.4K +117.9K (+373.5%) | 307.8K +257.6K (+513.4%) | 0.08% +0.061 pp | 0.00% +0.000 pp | USD1.96 +5.1% | 8 qtrs — |
| 61 | DEUTSCHE BANK AG\ | 147.8K +11.5K (+8.4%) | 304.4K +87.7K (+40.5%) | 0.08% +0.006 pp | 0.00% +0.000 pp | USD2.53 -18.6% | 50 qtrs — |
| 62 | ENGINEERS GATE MANAGER LP | 143.0K +6.4K (+4.7%) | 294.5K +77.4K (+35.6%) | 0.07% +0.003 pp | 0.00% +0.001 pp | USD3.11 -33.8% | 26 qtrs — |
| 63 | CWM, LLC | 129.1K +8.2K (+6.8%) | 266.0K +74.0K (+38.5%) | 0.07% +0.004 pp | 0.00% +0.000 pp | USD1.48 +39.2% | 7 qtrs — |
| 64 | CERITY PARTNERS LLC | 124.0K +18.4K (+17.4%) | 255.4K +87.5K (+52.1%) | 0.06% +0.009 pp | 0.00% +0.000 pp | USD1.65 +24.8% | 8 qtrs — |
| 65 | COLONY GROUP, LLC | 120.7K +18.4K (+18.0%) | 248.7K +69.2K (+38.6%) | 0.06% +0.010 pp | 0.00% +0.000 pp | USD1.91 +7.9% | 9 qtrs — |
| 66 | PRICE T ROWE ASSOCIATES INC /MD/ | 111.0K +17.8K (+19.1%) | 229.0K +80.0K (+53.7%) | 0.06% +0.009 pp | 0.00% +0.000 pp | USD3.29 -37.4% | 75 qtrs — |
| 67 | SQUAREPOINT OPS LLC | 102.0K +102.0K (+100.0%) | 210.1K +210.1K (+100.0%) | 0.05% +0.053 pp | 0.00% +0.000 pp | USD2.06 +0.0% | 1 qtrs NEW |
| 68 | BNP PARIBAS ARBITRAGE, SNC | 97.6K +31.3K (+47.1%) | 201.1K +95.6K (+90.6%) | 0.05% +0.016 pp | 0.00% +0.000 pp | USD1.96 +5.1% | 46 qtrs — |
| 69 | STEPHENS INC /AR/ | 96.5K -2.0K (-2.0%) | 198.9K +42.3K (+27.0%) | 0.05% -0.001 pp | 0.00% +0.001 pp | USD5.70 -63.9% | 30 qtrs — |
| 70 | PANAGORA ASSET MANAGEMENT INC | 92.5K +92.5K (+100.0%) | 190.6K +190.6K (+100.0%) | 0.05% +0.048 pp | 0.00% +0.001 pp | USD2.06 +0.0% | 1 qtrs NEW |
| 71 | METLIFE INVESTMENT MANAGEMENT, LLC | 91.6K +8.4K (+10.1%) | 188.7K +56.5K (+42.7%) | 0.05% +0.004 pp | 0.00% +0.000 pp | USD2.55 -19.2% | 33 qtrs — |
| 72 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 85.7K -2.4K (-2.8%) | 176.6K +36.4K (+26.0%) | 0.04% -0.001 pp | 0.00% +0.000 pp | USD1.70 +21.2% | 7 qtrs — |
| 73 | JOEL ISAACSON & CO., LLC | 85.0K -15.0K (-15.0%) | 175.1K +16.1K (+10.1%) | 0.04% -0.008 pp | 0.01% +0.000 pp | USD2.41 -14.5% | 13 qtrs — |
| 74 | FIRST MANHATTAN CO. LLC. | 82.0K +— (+0.0%) | 168.9K +38.5K (+29.6%) | 0.04% 0.000 pp | 0.00% +0.000 pp | USD3.97 -48.1% | 51 qtrs — |
| 75 | WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 81.6K +6.1K (+8.1%) | 168.8K +48.1K (+39.8%) | 0.04% +0.003 pp | 0.00% +0.000 pp | USD1.47 +40.1% | 5 qtrs — |
| 76 | CITIGROUP INC | 81.2K +73.0K (+886.0%) | 167.3K +154.2K (+1,177.5%) | 0.04% +0.038 pp | 0.00% +0.000 pp | USD2.04 +1.0% | 54 qtrs — |
| 77 | INTECH INVESTMENT MANAGEMENT LLC | 73.5K -19.9K (-21.3%) | 151.3K +2.9K (+2.0%) | 0.04% -0.011 pp | 0.00% +0.000 pp | USD1.54 +33.8% | 6 qtrs — |
| 78 | VERITION FUND MANAGEMENT LLC | 70.3K +— (+0.0%) | 144.7K +33.0K (+29.6%) | 0.04% 0.000 pp | 0.00% +0.000 pp | USD1.39 +48.2% | 4 qtrs — |
| 79 | RUSSELL INVESTMENTS GROUP, LTD. | 65.4K -2.5K (-3.7%) | 134.8K +26.7K (+24.7%) | 0.03% -0.001 pp | 0.00% +0.000 pp | USD1.44 +43.1% | 12 qtrs — |
| 80 | SG AMERICAS SECURITIES, LLC | 61.3K +21.2K (+52.9%) | 126.0K +62.0K (+96.9%) | 0.03% +0.011 pp | 0.00% 0.000 pp | USD1.77 +16.4% | 37 qtrs — |
| 81 | POLICE & FIREMEN'S RETIREMENT SYSTEM OF NEW JERSEY | 59.8K -986.0 (-1.6%) | 123.1K +26.5K (+27.5%) | 0.03% -0.001 pp | 0.00% +0.000 pp | USD1.56 +32.1% | 5 qtrs — |
| 82 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 59.6K -10.3K (-14.7%) | 122.8K +11.7K (+10.5%) | 0.03% -0.006 pp | 0.00% +0.000 pp | USD4.05 -49.1% | 51 qtrs — |
| 83 | MARINER, LLC | 54.5K +14.0K (+34.5%) | 112.5K +48.0K (+74.5%) | 0.03% +0.007 pp | 0.00% +0.000 pp | USD1.58 +30.4% | 3 qtrs — |
| 84 | MERCER GLOBAL ADVISORS INC /ADV | 53.0K +17.3K (+48.6%) | 109.2K +52.5K (+92.5%) | 0.03% +0.009 pp | 0.00% +0.000 pp | USD1.69 +21.9% | 3 qtrs — |
| 85 | MACKENZIE FINANCIAL CORP | 52.1K +— (+0.0%) | 108.7K +25.8K (+31.2%) | 0.03% 0.000 pp | 0.00% +0.000 pp | USD2.27 -9.3% | 24 qtrs — |
| 86 | JANNEY MONTGOMERY SCOTT LLC | 48.2K -750.0 (-1.5%) | 99.0K +21.0K (+26.9%) | 0.03% -0.001 pp | 0.00% +0.000 pp | USD4.66 -55.8% | 56 qtrs — |
| 87 | CAITONG INTERNATIONAL ASSET MANAGEMENT CO., LTD | 46.8K +35.7K (+321.3%) | 96.4K +78.7K (+445.8%) | 0.02% +0.019 pp | 0.02% +0.011 pp | USD1.95 +5.6% | 4 qtrs — |
| 88 | NEW YORK STATE COMMON RETIREMENT FUND | 45.2K +— (+0.0%) | 93.1K +21.2K (+29.6%) | 0.02% 0.000 pp | 0.00% +0.000 pp | USD5.38 -61.7% | 44 qtrs — |
| 89 | STEWARD PARTNERS INVESTMENT ADVISORY, LLC | 44.8K +39.0K (+677.1%) | 92.2K +83.0K (+906.8%) | 0.02% +0.020 pp | 0.00% +0.001 pp | USD2.45 -15.9% | 27 qtrs — |
| 90 | LPL FINANCIAL LLC | 44.1K +350.0 (+0.8%) | 90.9K +21.3K (+30.6%) | 0.02% +0.000 pp | 0.00% +0.000 pp | USD2.83 -27.2% | 23 qtrs — |
| 91 | R SQUARED LTD | 39.0K -38.8K (-49.9%) | 80.3K -43.4K (-35.1%) | 0.02% -0.020 pp | 0.04% -0.016 pp | USD1.49 +38.3% | 5 qtrs — |
| 92 | CAPTRUST FINANCIAL ADVISORS | 37.1K +4.9K (+15.3%) | 76.3K +25.2K (+49.4%) | 0.02% +0.003 pp | 0.00% +0.000 pp | USD1.49 +38.3% | 4 qtrs — |
| 93 | CREATIVE PLANNING | 35.5K +21.5K (+152.7%) | 73.2K +50.8K (+227.3%) | 0.02% +0.011 pp | 0.00% +0.000 pp | USD1.87 +10.2% | 2 qtrs — |
| 94 | LAIRD NORTON TRUST COMPANY, LLC | 33.9K +33.9K (+100.0%) | 69.8K +69.8K (+100.0%) | 0.02% +0.018 pp | 0.00% +0.002 pp | USD2.06 +0.0% | 1 qtrs NEW |
| 95 | PROSHARE ADVISORS LLC | 33.6K +2.0K (+6.5%) | 69.3K +19.0K (+37.9%) | 0.02% +0.001 pp | 0.00% +0.000 pp | USD2.87 -28.2% | 55 qtrs — |
| 96 | PUBLIC EMPLOYEES RETIREMENT ASSOCIATION OF COLORADO | 32.4K +— (+0.0%) | 67.0K +16.0K (+31.4%) | 0.02% +0.000 pp | 0.00% +0.000 pp | USD2.97 -30.6% | 12 qtrs — |
| 97 | PALLAS CAPITAL ADVISORS LLC | 31.5K +1.7K (+5.5%) | 64.9K +17.4K (+36.7%) | 0.02% +0.001 pp | 0.00% +0.000 pp | USD1.43 +44.1% | 4 qtrs — |
| 98 | CITADEL ADVISORS LLC | 31.4K +14.1K (+81.5%) | 64.7K +37.2K (+135.2%) | 0.02% +0.007 pp | 0.00% +0.000 pp | USD1.96 +5.1% | 38 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 64 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | ARK Genomic Revolution ETF ARKG | 1.32% | 17.22M | 0.75% |
| 2 | ROBO Global Healthcare Technology and Innovation ETF HTEC | 0.87% | 431.7K | 0.68% |
| 3 | State Street SPDR S&P Health Care Equipment ETF XHE | 0.64% | 974.2K | 0.35% |
| 4 | Franklin Small Cap Enhanced ETF FSML | 0.60% | 901.5K | 0.45% |
| 5 | Invesco NASDAQ Future Gen 200 ETF QQQS | 0.51% | 112.6K | 0.20% |
| 6 | ARK Innovation ETF ARKK | 0.41% | 26.85M | 0.75% |
| 7 | iShares Micro-Cap ETF IWC | 0.14% | 2.09M | 0.60% |
| 8 | Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF GSSC | 0.10% | 1.02M | 0.20% |
| 9 | Fidelity Enhanced Small Cap ETF FESM | 0.06% | 3.58M | 0.28% |
| 10 | iShares U.S. Small-Cap Equity Factor ETF SMLF | 0.06% | 2.53M | 0.15% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
2
Sells
0
Shares acquired
400.0K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+400,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-01 | Jensen Chrystal | Officer | A-Award | A | Common Stock | 200,000 | 0.00 | — | 1,146,131 | D | ↗ |
| 2026-04-01 | Green Kevin Dennis | Officer | A-Award | A | Common Stock | 200,000 | 0.00 | — | 1,240,551 | D | ↗ |
| 2026-03-12 | Jayaraman Vivek K | Officer | S-Sale | D | Common Stock | 165,200 | 1.66 | 273.8K | 1,747,674 | D | ↗ |
| 2026-03-12 | Greenman William Mariner | Director / Officer | S-Sale | D | Common Stock | 447,757 | 1.66 | 742.0K | 4,998,493 | D | ↗ |
| 2026-03-12 | Green Kevin Dennis | Officer | S-Sale | D | Common Stock | 127,544 | 1.66 | 211.4K | 1,040,551 | D | ↗ |
| 2026-03-12 | Benjamin Richard J | Officer | S-Sale | D | Common Stock | 101,740 | 1.66 | 168.6K | 777,361 | D | ↗ |
| 2026-03-09 | Benjamin Richard J | Officer | S-Sale | D | Common Stock | 40,426 | 1.88 | 76.0K | 879,101 | D | ↗ |
| 2026-03-06 | Jensen Chrystal | Officer | S-Sale | D | Common Stock | 30,845 | 2.01 | 61.9K | 1,059,139 | D | ↗ |
| 2026-03-06 | Jayaraman Vivek K | Officer | S-Sale | D | Common Stock | 34,094 | 2.01 | 68.4K | 1,912,874 | D | ↗ |
| 2026-03-06 | Greenman William Mariner | Director / Officer | S-Sale | D | Common Stock | 78,187 | 2.01 | 156.8K | 5,446,250 | D | ↗ |
| 2026-03-06 | Green Kevin Dennis | Officer | S-Sale | D | Common Stock | 27,796 | 2.01 | 55.7K | 1,168,095 | D | ↗ |
| 2026-03-06 | Benjamin Richard J | Officer | S-Sale | D | Common Stock | 24,235 | 2.01 | 48.6K | 919,527 | D | ↗ |
| 2026-03-05 | Jensen Chrystal | Officer | A-Award | A | Common Stock | 55,220 | 0.00 | — | 1,083,514 | D | ↗ |
| 2026-03-05 | Jayaraman Vivek K | Officer | A-Award | A | Common Stock | 80,320 | 0.00 | — | 1,946,968 | D | ↗ |
| 2026-03-05 | Greenman William Mariner | Director / Officer | A-Award | A | Common Stock | 193,270 | 0.00 | — | 5,524,437 | D | ↗ |
| 2026-03-05 | Green Kevin Dennis | Officer | S-Sale | D | Common Stock | 55,225 | 2.06 | 113.9K | 1,195,891 | D | ↗ |
| 2026-03-05 | Benjamin Richard J | Officer | S-Sale | D | Common Stock | 61,233 | 2.06 | 126.3K | 943,762 | D | ↗ |
| 2026-03-02 | Jensen Chrystal | Officer | A-Award | A | Common Stock | 300,000 | 0.00 | — | 1,028,294 | D | ↗ |
| 2026-03-02 | Jayaraman Vivek K | Officer | A-Award | A | Common Stock | 420,000 | 0.00 | — | 1,866,648 | D | ↗ |
| 2026-03-02 | Greenman William Mariner | Director / Officer | A-Award | A | Common Stock | 1,200,000 | 0.00 | — | 5,331,167 | D | ↗ |
| 2026-03-02 | Green Kevin Dennis | Officer | A-Award | A | Common Stock | 300,000 | 0.00 | — | 1,187,262 | D | ↗ |
| 2026-03-02 | Benjamin Richard J | Officer | A-Award | A | Common Stock | 264,000 | 0.00 | — | 949,775 | D | ↗ |
| 2025-11-24 | Jensen Chrystal | Officer | S-Sale | D | Common Stock | 55,000 | 1.70 | 93.5K | 728,294 | D | ↗ |
| 2025-08-25 | Gregory Dean A. | Director | P-Purchase | A | Common Stock | 25,000 | 1.25 | 31.3K | 86,725 | D | ↗ |
| 2025-06-03 | Witney Frank | Director | A-Award | A | Common Stock | 60,000 | 0.00 | — | 280,059 | D | ↗ |
| 2025-06-03 | Swisher Daniel N JR | Director | A-Award | A | Common Stock | 60,000 | 0.00 | — | 207,045 | D | ↗ |
| 2025-06-03 | Shan Hua | Director | A-Award | A | Common Stock | 60,000 | 0.00 | — | 132,386 | D | ↗ |
| 2025-06-03 | NACHTSHEIM JAMI K | Director | A-Award | A | Common Stock | 60,000 | 0.00 | — | 208,362 | D | ↗ |
| 2025-06-03 | MOORE TIMOTHY L. | Director | A-Award | A | Common Stock | 60,000 | 0.00 | — | 205,073 | D | ↗ |
| 2025-06-03 | Lucena Ann | Director | A-Award | A | Common Stock | 60,000 | 0.00 | — | 172,284 | D | ↗ |
| 2025-06-03 | BJERKHOLT ERIC | Director | A-Award | A | Common Stock | 60,000 | 0.00 | — | 222,133 | D | ↗ |
| 2025-03-14 | Jensen Chrystal | Officer | S-Sale | D | Common Stock | 30,075 | 1.45 | 43.6K | 783,294 | D | ↗ |
| 2025-03-14 | Jayaraman Vivek K | Officer | S-Sale | D | Common Stock | 46,004 | 1.45 | 66.7K | 1,431,326 | D | ↗ |
| 2025-03-14 | Greenman William Mariner | Director / Officer | S-Sale | D | Common Stock | 122,827 | 1.45 | 178.1K | 4,115,845 | D | ↗ |
| 2025-03-14 | Green Kevin Dennis | Officer | S-Sale | D | Common Stock | 36,740 | 1.45 | 53.3K | 875,867 | D | ↗ |
| 2025-03-14 | Benjamin Richard J | Officer | S-Sale | D | Common Stock | 30,075 | 1.45 | 43.6K | 685,775 | D | ↗ |
| 2025-03-13 | Jensen Chrystal | Officer | S-Sale | D | Common Stock | 18,949 | 1.45 | 27.5K | 813,369 | D | ↗ |
| 2025-03-13 | Jayaraman Vivek K | Officer | S-Sale | D | Common Stock | 29,985 | 1.45 | 43.5K | 1,477,330 | D | ↗ |
| 2025-03-13 | Greenman William Mariner | Director / Officer | S-Sale | D | Common Stock | 71,086 | 1.45 | 103.1K | 4,238,672 | D | ↗ |
| 2025-03-13 | Green Kevin Dennis | Officer | S-Sale | D | Common Stock | 23,147 | 1.45 | 33.6K | 912,607 | D | ↗ |
| 2025-03-13 | Benjamin Richard J | Officer | S-Sale | D | Common Stock | 18,949 | 1.45 | 27.5K | 715,850 | D | ↗ |
| 2025-03-12 | Jensen Chrystal | Officer | S-Sale | D | Common Stock | 113,008 | 1.66 | 187.3K | 946,131 | D | ↗ |
| 2025-03-07 | Jensen Chrystal | Officer | S-Sale | D | Common Stock | 27,457 | 1.50 | 41.1K | 832,318 | D | ↗ |
| 2025-03-07 | Jayaraman Vivek K | Officer | S-Sale | D | Common Stock | 33,999 | 1.50 | 50.9K | 1,507,315 | D | ↗ |
| 2025-03-07 | Greenman William Mariner | Director / Officer | S-Sale | D | Common Stock | 60,984 | 1.50 | 91.4K | 4,309,758 | D | ↗ |
| 2025-03-07 | Green Kevin Dennis | Officer | S-Sale | D | Common Stock | 31,148 | 1.50 | 46.7K | 935,754 | D | ↗ |
| 2025-03-07 | Benjamin Richard J | Officer | S-Sale | D | Common Stock | 26,139 | 1.50 | 39.2K | 734,799 | D | ↗ |
| 2025-03-06 | Jensen Chrystal | Officer | A-Award | A | Common Stock | 385,000 | 0.00 | — | 790,198 | D | ↗ |
| 2025-03-06 | Jayaraman Vivek K | Officer | A-Award | A | Common Stock | 545,000 | 0.00 | — | 1,450,828 | D | ↗ |
| 2025-03-06 | Greenman William Mariner | Director / Officer | A-Award | A | Common Stock | 165,742 | 0.00 | — | 4,370,742 | D | ↗ |
| 2025-03-06 | Green Kevin Dennis | Officer | A-Award | A | Common Stock | 80,540 | 0.00 | — | 966,902 | D | ↗ |
| 2025-03-06 | Benjamin Richard J | Officer | A-Award | A | Common Stock | 300,000 | 0.00 | — | 694,373 | D | ↗ |
| 2025-03-04 | Jensen Chrystal | Officer | S-Sale | D | Common Stock | 60,000 | 1.59 | 95.1K | 405,198 | D | ↗ |
| 2025-03-04 | Jayaraman Vivek K | Officer | S-Sale | D | Common Stock | 10,780 | 1.55 | 16.7K | 905,828 | D | ↗ |
| 2025-03-04 | Greenman William Mariner | Director / Officer | S-Sale | D | Common Stock | 23,023 | 1.55 | 35.7K | 3,230,000 | D | ↗ |
| 2025-03-04 | Green Kevin Dennis | Officer | S-Sale | D | Common Stock | 8,386 | 1.55 | 13.0K | 554,518 | D | ↗ |
| 2025-03-04 | Benjamin Richard J | Officer | S-Sale | D | Common Stock | 6,292 | 1.55 | 9.7K | 394,373 | D | ↗ |
| 2025-03-03 | Jensen Chrystal | Officer | M-Exempt | D | Restricted Stock Unit | 13,912 | 0.00 | — | 0 | D | ↗ |
| 2025-03-03 | Jayaraman Vivek K | Officer | M-Exempt | A | Common Stock | 23,850 | 0.00 | — | 916,608 | D | ↗ |
| 2025-03-03 | Greenman William Mariner | Director / Officer | M-Exempt | A | Common Stock | 57,637 | 0.00 | — | 3,253,023 | D | ↗ |
| 2025-03-03 | Green Kevin Dennis | Officer | M-Exempt | A | Common Stock | 18,550 | 0.00 | — | 562,904 | D | ↗ |
| 2025-03-03 | Benjamin Richard J | Officer | M-Exempt | D | Restricted Stock Unit | 13,912 | 0.00 | — | 0 | D | ↗ |
| 2025-02-26 | Jensen Chrystal | Officer | A-Award | A | Restricted Stock Unit | 13,912 | 0.00 | — | 13,912 | D | ↗ |
| 2025-02-26 | Jayaraman Vivek K | Officer | A-Award | A | Restricted Stock Unit | 23,850 | 0.00 | — | 23,850 | D | ↗ |
| 2025-02-26 | Greenman William Mariner | Director / Officer | A-Award | A | Restricted Stock Unit | 57,637 | 0.00 | — | 57,637 | D | ↗ |
| 2025-02-26 | Green Kevin Dennis | Officer | A-Award | A | Restricted Stock Unit | 18,550 | 0.00 | — | 18,550 | D | ↗ |
| 2025-02-26 | Benjamin Richard J | Officer | A-Award | A | Restricted Stock Unit | 13,912 | 0.00 | — | 13,912 | D | ↗ |
| 2024-12-16 | Jensen Chrystal | Officer | S-Sale | D | Common Stock | 16,667 | 1.71 | 28.5K | 457,578 | D | ↗ |
| 2024-12-13 | Gregory Dean A. | Director | P-Purchase | A | Common Stock | 1,725 | 1.70 | 2.9K | 61,725 | D | ↗ |
| 2024-12-12 | BJERKHOLT ERIC | Director | S-Sale | D | Common Stock | 20,000 | 1.79 | 35.7K | 162,133 | D | ↗ |
| 2024-09-04 | Green Kevin Dennis | Officer | S-Sale | D | Common Stock | 54,272 | 2.15 | 116.8K | 536,093 | — | ↗ |
| 2024-09-03 | Green Kevin Dennis | Officer | S-Sale | D | Common Stock | 28,385 | 2.18 | 61.9K | 590,365 | — | ↗ |
| 2024-08-15 | Jensen Chrystal | Officer | S-Sale | D | Common Stock | 16,667 | 2.07 | 34.4K | 474,245 | — | ↗ |
| 2024-08-02 | Benjamin Richard J | Officer | S-Sale | D | Common Stock | 21,605 | 2.50 | 54.0K | 438,007 | — | ↗ |
| 2024-07-01 | Gregory Dean A. | Director | A-Award | A | Common Stock | 60,000 | 0.00 | — | 60,000 | — | ↗ |
| 2024-06-05 | Witney Frank | Director | A-Award | A | Common Stock | 40,000 | 5.00 | 200.0K | 220,059 | — | ↗ |
| 2024-06-05 | Swisher Daniel N JR | Director | A-Award | A | Common Stock | 40,000 | 5.00 | 200.0K | 147,045 | — | ↗ |
| 2024-06-05 | Shan Hua | Director | A-Award | A | Common Stock | 40,000 | 5.00 | 200.0K | 72,386 | — | ↗ |
| 2024-06-05 | SCHULZE GAIL | Director | A-Award | A | Common Stock | 40,000 | 5.00 | 200.0K | 163,420 | — | ↗ |
| 2024-06-05 | NACHTSHEIM JAMI K | Director | A-Award | A | Common Stock | 40,000 | 5.00 | 200.0K | 148,362 | — | ↗ |
| 2024-06-05 | MOORE TIMOTHY L. | Director | A-Award | A | Common Stock | 40,000 | 5.00 | 200.0K | 145,073 | — | ↗ |
| 2024-06-05 | Lucena Ann | Director | A-Award | A | Common Stock | 40,000 | 5.00 | 200.0K | 112,284 | — | ↗ |
| 2024-06-05 | BJERKHOLT ERIC | Director | A-Award | A | Common Stock | 40,000 | 5.00 | 200.0K | 182,133 | — | ↗ |
| 2024-05-13 | Shan Hua | Director | P-Purchase | A | Common Stock | 2,500 | 1.99 | 5.0K | 32,386 | — | ↗ |
| 2024-05-10 | NACHTSHEIM JAMI K | Director | P-Purchase | A | Common Stock | 2,000 | 1.79 | 3.6K | 108,362 | — | ↗ |
| 2024-05-09 | Witney Frank | Director | P-Purchase | A | Common Stock | 20,000 | 1.89 | 37.8K | 180,059 | — | ↗ |
| 2024-05-09 | Swisher Daniel N JR | Director | P-Purchase | A | Common Stock | 2,500 | 1.88 | 4.7K | 107,045 | — | ↗ |
| 2024-03-14 | Jensen Chrystal | Officer | S-Sale | D | Common Stock | 17,824 | 1.97 | 35.2K | 490,912 | — | ↗ |
| 2024-03-14 | Jayaraman Vivek K | Officer | S-Sale | D | Common Stock | 26,794 | 1.97 | 52.9K | 878,653 | — | ↗ |
| 2024-03-14 | Greenman William Mariner | Director / Officer | S-Sale | D | Common Stock | 63,611 | 2.02 | 128.2K | 3,181,281 | — | ↗ |
| 2024-03-14 | Green Kevin Dennis | Officer | S-Sale | D | Common Stock | 21,497 | 1.97 | 42.4K | 618,750 | — | ↗ |
| 2024-03-14 | CORASH LAURENCE M | Officer | S-Sale | D | Common Stock | 14,360 | 1.97 | 28.4K | 2,339,740 | — | ↗ |
| 2024-03-14 | Benjamin Richard J | Officer | S-Sale | D | Common Stock | 17,738 | 1.97 | 35.0K | 459,612 | — | ↗ |
| 2024-03-13 | Moore Carol | Officer | S-Sale | D | Common Stock | 10,416 | 1.97 | 20.6K | 490,623 | — | ↗ |
| 2024-03-13 | Jensen Chrystal | Officer | S-Sale | D | Common Stock | 17,460 | 2.06 | 35.9K | 508,736 | — | ↗ |
| 2024-03-13 | Jayaraman Vivek K | Officer | S-Sale | D | Common Stock | 26,247 | 2.06 | 54.0K | 905,447 | — | ↗ |
| 2024-03-13 | Greenman William Mariner | Director / Officer | S-Sale | D | Common Stock | 62,315 | 2.06 | 128.2K | 3,244,892 | — | ↗ |
| 2024-03-13 | Green Kevin Dennis | Officer | S-Sale | D | Common Stock | 21,058 | 2.02 | 42.4K | 640,247 | — | ↗ |
| 2024-03-13 | CORASH LAURENCE M | Officer | S-Sale | D | Common Stock | 14,067 | 2.06 | 28.9K | 2,354,100 | — | ↗ |
| 2024-03-13 | Benjamin Richard J | Officer | S-Sale | D | Common Stock | 17,377 | 2.06 | 35.7K | 477,350 | — | ↗ |
| 2024-03-12 | Moore Carol | Officer | M-Exempt | A | Common Stock | 11,666 | 0.00 | — | 511,242 | — | ↗ |
| 2024-03-12 | Jensen Chrystal | Officer | M-Exempt | A | Common Stock | 16,666 | 0.00 | — | 526,196 | — | ↗ |
| 2024-03-12 | Jayaraman Vivek K | Officer | M-Exempt | D | Restricted Stock Unit | 25,000 | 0.00 | — | 0 | — | ↗ |
| 2024-03-12 | Greenman William Mariner | Director / Officer | M-Exempt | D | Restricted Stock Unit | 64,666 | 0.00 | — | 0 | — | ↗ |
| 2024-03-12 | Green Kevin Dennis | Officer | M-Exempt | A | Common Stock | 21,666 | 0.00 | — | 661,305 | — | ↗ |
| 2024-03-12 | CORASH LAURENCE M | Officer | M-Exempt | A | Common Stock | 16,666 | 0.00 | — | 2,368,167 | — | ↗ |
| 2024-03-12 | Benjamin Richard J | Officer | M-Exempt | D | Restricted Stock Unit | 16,666 | 0.00 | — | 0 | — | ↗ |
| 2024-03-08 | Benjamin Richard J | Officer | S-Sale | D | Common Stock | 29,378 | 2.40 | 70.5K | 478,061 | — | ↗ |
| 2024-03-01 | Moore Carol | Officer | A-Award | A | Restricted Stock Unit | 75,000 | 0.00 | — | 499,576 | — | ↗ |
| 2024-03-01 | Menard Chrystal | Officer | A-Award | A | Restricted Stock Unit | 160,000 | 0.00 | — | 509,530 | — | ↗ |
| 2024-03-01 | Jayaraman Vivek K | Officer | A-Award | A | Restricted Stock Unit | 240,000 | 0.00 | — | 906,694 | — | ↗ |
| 2024-03-01 | Greenman William Mariner | Director / Officer | A-Award | A | Restricted Stock Unit | 575,000 | 0.00 | — | 3,242,541 | — | ↗ |
| 2024-03-01 | Green Kevin Dennis | Officer | A-Award | A | Restricted Stock Unit | 200,000 | 0.00 | — | 639,639 | — | ↗ |
| 2024-03-01 | CORASH LAURENCE M | Officer | A-Award | A | Restricted Stock Unit | 90,000 | 0.00 | — | 2,351,501 | — | ↗ |
| 2024-03-01 | Benjamin Richard J | Officer | A-Award | A | Restricted Stock Unit | 160,000 | 0.00 | — | 507,439 | — | ↗ |
| 2023-12-13 | BJERKHOLT ERIC | Director | P-Purchase | A | Common Stock | 10,000 | 1.62 | 16.2K | 142,133 | — | ↗ |
| 2023-08-22 | Lucena Ann | Director | P-Purchase | A | Common Stock | 7,500 | 1.69 | 12.6K | 72,284 | — | ↗ |
| 2023-08-21 | BJERKHOLT ERIC | Director | P-Purchase | A | Common Stock | 10,000 | 1.72 | 17.2K | 132,133 | — | ↗ |
| 2023-06-07 | Witney Frank | Director | A-Award | A | Common Stock | 40,000 | 5.00 | 200.0K | 160,059 | — | ↗ |
| 2023-06-07 | Swisher Daniel N JR | Director | A-Award | A | Common Stock | 40,000 | 5.00 | 200.0K | 104,545 | — | ↗ |
| 2023-06-07 | SCHULZE GAIL | Director | A-Award | A | Common Stock | 40,000 | 5.00 | 200.0K | 123,420 | — | ↗ |
| 2023-06-07 | NACHTSHEIM JAMI K | Director | A-Award | A | Common Stock | 40,000 | 5.00 | 200.0K | 106,362 | — | ↗ |
| 2023-06-07 | MOORE TIMOTHY L. | Director | A-Award | A | Common Stock | 40,000 | 5.00 | 200.0K | 105,073 | — | ↗ |
| 2023-06-07 | Lucena Ann | Director | A-Award | A | Common Stock | 40,000 | 5.00 | 200.0K | 64,784 | — | ↗ |
| 2023-06-07 | BJERKHOLT ERIC | Director | A-Award | A | Common Stock | 40,000 | 5.00 | 200.0K | 122,133 | — | ↗ |
| 2023-05-26 | Swisher Daniel N JR | Director | P-Purchase | A | Common Stock | 5,000 | 1.91 | 9.5K | 118,808 | — | ↗ |
| 2023-05-24 | SCHULZE GAIL | Director | P-Purchase | A | Common Stock | 9,850 | 2.03 | 20.0K | 83,420 | — | ↗ |
| 2023-05-23 | BJERKHOLT ERIC | Director | P-Purchase | A | Common Stock | 5,000 | 2.00 | 10.0K | 82,133 | — | ↗ |
| 2023-03-13 | Moore Carol | Officer | S-Sale | D | Common Stock | 3,350 | 2.80 | 9.4K | 415,915 | — | ↗ |
| 2023-03-13 | Menard Chrystal | Officer | S-Sale | D | Common Stock | 5,758 | 2.80 | 16.1K | 349,530 | — | ↗ |
| 2023-03-13 | Jayaraman Vivek K | Officer | S-Sale | D | Common Stock | 16,565 | 2.80 | 46.4K | 641,861 | — | ↗ |
| 2023-03-13 | Greenman William Mariner | Director / Officer | S-Sale | D | Common Stock | 22,732 | 2.80 | 63.6K | 2,658,346 | — | ↗ |
| 2023-03-13 | Green Kevin Dennis | Officer | S-Sale | D | Common Stock | 9,662 | 2.80 | 27.1K | 421,797 | — | ↗ |
| 2023-03-13 | CORASH LAURENCE M | Officer | S-Sale | D | Common Stock | 5,745 | 2.80 | 16.1K | 2,261,501 | — | ↗ |
| 2023-03-13 | Benjamin Richard J | Officer | S-Sale | D | Common Stock | 5,747 | 2.80 | 16.1K | 357,439 | — | ↗ |
| 2023-03-12 | Moore Carol | Officer | M-Exempt | A | Common Stock | 23,460 | 0.00 | — | 417,326 | — | ↗ |
| 2023-03-12 | Menard Chrystal | Officer | M-Exempt | A | Common Stock | 16,667 | 0.00 | — | 355,288 | — | ↗ |
| 2023-03-12 | Jayaraman Vivek K | Officer | M-Exempt | D | Restricted Stock Unit | 44,200 | 0.00 | — | 0 | — | ↗ |
| 2023-03-12 | Greenman William Mariner | Director / Officer | M-Exempt | A | Common Stock | 64,667 | 0.00 | — | 2,681,078 | — | ↗ |
| 2023-03-12 | Green Kevin Dennis | Officer | M-Exempt | D | Restricted Stock Unit | 21,667 | 0.00 | — | 21,666 | — | ↗ |
| 2023-03-12 | CORASH LAURENCE M | Officer | M-Exempt | D | Restricted Stock Unit | 23,460 | 0.00 | — | 0 | — | ↗ |
| 2023-03-12 | Benjamin Richard J | Officer | M-Exempt | A | Common Stock | 23,460 | 0.00 | — | 356,125 | — | ↗ |
| 2023-03-01 | Moore Carol | Officer | A-Award | A | Restricted Stock Unit | 110,000 | 0.00 | — | 393,866 | — | ↗ |
| 2023-03-01 | Menard Chrystal | Officer | A-Award | A | Restricted Stock Unit | 160,000 | 0.00 | — | 324,871 | — | ↗ |
| 2023-03-01 | Jayaraman Vivek K | Officer | A-Award | A | Restricted Stock Unit | 240,000 | 0.00 | — | 614,226 | — | ↗ |
| 2023-03-01 | Greenman William Mariner | Director / Officer | A-Award | A | Restricted Stock Unit | 575,000 | 0.00 | — | 2,546,634 | — | ↗ |
| 2023-03-01 | Green Kevin Dennis | Officer | A-Award | A | Restricted Stock Unit | 185,000 | 0.00 | — | 407,999 | — | ↗ |
| 2023-03-01 | CORASH LAURENCE M | Officer | A-Award | A | Restricted Stock Unit | 110,000 | 0.00 | — | 2,236,716 | — | ↗ |
| 2023-03-01 | Benjamin Richard J | Officer | A-Award | A | Restricted Stock Unit | 160,000 | 0.00 | — | 332,665 | — | ↗ |
| 2022-12-28 | SCHULZE GAIL | Director | M-Exempt | A | Common Stock | 25,000 | 3.19 | 79.8K | 73,570 | — | ↗ |
| 2022-11-10 | Swisher Daniel N JR | Director | M-Exempt | A | Common Stock | 12,500 | 3.19 | 39.9K | 126,308 | — | ↗ |
| 2022-08-15 | Menard Chrystal | Officer | S-Sale | D | Common Stock | 10,000 | 5.18 | 51.8K | 164,871 | — | ↗ |
| 2022-08-09 | Benjamin Richard J | Officer | S-Sale | D | Common Stock | 10,000 | 5.12 | 51.2K | 172,665 | — | ↗ |
| 2022-07-01 | Shan Hua | Director | A-Award | A | Option (Right to Buy) | 58,074 | 0.00 | — | 58,074 | — | ↗ |
| 2022-06-01 | Witney Frank | Director | A-Award | A | Common Stock | 20,454 | 0.00 | — | 120,059 | — | ↗ |
| 2022-06-01 | Swisher Daniel N JR | Director | A-Award | A | Option (Right to Buy) | 39,866 | 0.00 | — | 39,866 | — | ↗ |
| 2022-06-01 | SCHULZE GAIL | Director | A-Award | A | Common Stock | 20,454 | 0.00 | — | 48,570 | — | ↗ |
| 2022-06-01 | NACHTSHEIM JAMI K | Director | A-Award | A | Option (Right to Buy) | 39,866 | 0.00 | — | 39,866 | — | ↗ |
| 2022-06-01 | MOORE TIMOTHY L. | Director | A-Award | A | Option (Right to Buy) | 39,866 | 0.00 | — | 39,866 | — | ↗ |
| 2022-06-01 | BJERKHOLT ERIC | Director | A-Award | A | Option (Right to Buy) | 39,866 | 0.00 | — | 39,866 | — | ↗ |
| 2022-05-10 | Green Kevin Dennis | Officer | S-Sale | D | Common Stock | 57,335 | 4.98 | 285.4K | 222,999 | — | ↗ |
| 2022-03-14 | Menard Chrystal | Officer | S-Sale | D | Common Stock | 8,173 | 5.04 | 41.2K | 164,186 | — | ↗ |
| 2022-03-14 | Greenman William Mariner | Director / Officer | S-Sale | D | Common Stock | 53,702 | 5.04 | 270.6K | 1,935,801 | — | ↗ |
| 2022-03-14 | Green Kevin Dennis | Officer | S-Sale | D | Common Stock | 16,152 | 5.04 | 81.4K | 251,847 | — | ↗ |
| 2022-03-14 | CORASH LAURENCE M | Officer | S-Sale | D | Common Stock | 16,152 | 5.04 | 81.4K | 2,101,434 | — | ↗ |
| 2022-03-12 | Moore Carol | Officer | S-Sale | D | Common Stock | 8,173 | 5.04 | 41.2K | 271,789 | — | ↗ |
| 2022-03-12 | Menard Chrystal | Officer | M-Exempt | A | Common Stock | 45,000 | 0.00 | — | 165,741 | — | ↗ |
| 2022-03-12 | Jayaraman Vivek K | Officer | M-Exempt | D | Restricted Stock Unit | 42,900 | 0.00 | — | 44,200 | — | ↗ |
| 2022-03-12 | Greenman William Mariner | Director / Officer | M-Exempt | A | Common Stock | 151,666 | 0.00 | — | 1,963,184 | — | ↗ |
| 2022-03-12 | Green Kevin Dennis | Officer | M-Exempt | D | Restricted Stock Unit | 22,770 | 0.00 | — | 23,460 | — | ↗ |
| 2022-03-12 | CORASH LAURENCE M | Officer | M-Exempt | D | Restricted Stock Unit | 45,000 | 0.00 | — | 0 | — | ↗ |
| 2022-03-12 | Benjamin Richard J | Officer | M-Exempt | A | Common Stock | 16,667 | 0.00 | — | 188,647 | — | ↗ |
| 2022-03-04 | NACHTSHEIM JAMI K | Director | M-Exempt | A | Common Stock | 5,127 | 0.00 | — | 45,908 | — | ↗ |
| 2022-03-01 | Moore Carol | Officer | A-Award | A | Option (Right to Buy) | 90,000 | 5.76 | 518.4K | 90,000 | — | ↗ |
| 2022-03-01 | Menard Chrystal | Officer | A-Award | A | Option (Right to Buy) | 105,000 | 5.76 | 604.8K | 105,000 | — | ↗ |
| 2022-03-01 | Jayaraman Vivek K | Officer | A-Award | A | Option (Right to Buy) | 180,000 | 5.76 | 1.04M | 180,000 | — | ↗ |
| 2022-03-01 | Greenman William Mariner | Director / Officer | A-Award | A | Common Stock | 217,500 | 0.00 | — | 1,811,518 | — | ↗ |
| 2022-03-01 | Green Kevin Dennis | Officer | A-Award | A | Option (Right to Buy) | 140,000 | 5.76 | 806.4K | 140,000 | — | ↗ |
| 2022-03-01 | CORASH LAURENCE M | Officer | A-Award | A | Restricted Stock Unit | 45,000 | 0.00 | — | 2,072,586 | — | ↗ |
| 2022-03-01 | Benjamin Richard J | Officer | A-Award | A | Option (Right to Buy) | 105,000 | 5.76 | 604.8K | 105,000 | — | ↗ |
| 2022-02-25 | Greenman William Mariner | Director / Officer | S-Sale | D | Common Stock | 93,000 | 5.73 | 532.6K | 1,594,018 | — | ↗ |
| 2022-01-03 | Moore Carol | Officer | M-Exempt | A | Common Stock | 19,059 | 3.66 | 69.8K | 200,335 | — | ↗ |
| 2021-12-28 | SCHULZE GAIL | Director | M-Exempt | D | Option (Right to Buy) | 25,000 | 0.00 | — | 0 | — | ↗ |
| 2021-12-17 | CORASH LAURENCE M | Officer | M-Exempt | A | Common Stock | 5,000 | 3.75 | 18.8K | 2,027,586 | — | ↗ |
| 2021-12-13 | CORASH LAURENCE M | Officer | M-Exempt | A | Common Stock | 40,000 | 3.75 | 150.0K | 2,022,586 | — | ↗ |
| 2021-11-09 | SCHULZE GAIL | Director | M-Exempt | A | Common Stock | 25,000 | 2.86 | 71.5K | 53,116 | — | ↗ |
| 2021-11-05 | Moore Carol | Officer | S-Sale | D | Common Stock | 110,000 | 7.94 | 873.2K | 181,276 | — | ↗ |
| 2021-11-03 | Menard Chrystal | Officer | S-Sale | D | Common Stock | 40,000 | 7.70 | 308.0K | 67,038 | — | ↗ |
| 2021-11-03 | Green Kevin Dennis | Officer | M-Exempt | A | Common Stock | 95,000 | 3.75 | 356.3K | 248,740 | — | ↗ |
| 2021-11-03 | Benjamin Richard J | Officer | M-Exempt | A | Common Stock | 33,333 | 4.33 | 144.3K | 109,368 | — | ↗ |
| 2021-09-05 | MOORE TIMOTHY L. | Director | M-Exempt | A | Common Stock | 4,296 | 0.00 | — | 44,619 | — | ↗ |
| 2021-08-06 | Lucena Ann | Director | A-Award | A | Common Stock | 24,784 | 0.00 | — | 24,784 | — | ↗ |
| 2021-08-04 | Swisher Daniel N JR | Director | M-Exempt | A | Common Stock | 12,877 | 2.86 | 36.8K | 106,231 | — | ↗ |
| 2021-08-03 | Greenman William Mariner | Director / Officer | M-Exempt | A | Common Stock | 100,000 | 2.08 | 208.0K | 1,518,672 | — | ↗ |
| 2021-06-02 | Witney Frank | Director | A-Award | A | Common Stock | 14,888 | 0.00 | — | 99,605 | — | ↗ |
| 2021-06-02 | Swisher Daniel N JR | Director | A-Award | A | Option (Right to Buy) | 35,295 | 5.62 | 198.4K | 35,295 | — | ↗ |
| 2021-06-02 | SCHULZE GAIL | Director | A-Award | A | Option (Right to Buy) | 29,983 | 5.62 | 168.5K | 29,983 | — | ↗ |
| 2021-06-02 | NACHTSHEIM JAMI K | Director | A-Award | A | Option (Right to Buy) | 29,983 | 5.62 | 168.5K | 29,983 | — | ↗ |
| 2021-06-02 | MOORE TIMOTHY L. | Director | A-Award | A | Option (Right to Buy) | 29,983 | 5.62 | 168.5K | 29,983 | — | ↗ |
| 2021-06-02 | BJERKHOLT ERIC | Director | A-Award | A | Option (Right to Buy) | 29,983 | 5.62 | 168.5K | 29,983 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-59.2K
Shares Outstanding
200.37M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | William M. Greenman President and Chief Executive Officer | 793.8K | — | 2.24M | — | 756.0K | 2.3K | 3.79M | 59.10% | ↗ |
| 2 | 2025 | Vivek Jayaraman Chief Operating Officer | 565.8K | — | 1.24M | — | 395.2K | 3.1K | 2.20M | 56.26% | ↗ |
| 3 | 2025 | Kevin D. Green Chief Financial Officer | 507.4K | — | 918.8K | — | 322.9K | 1.2K | 1.75M | 52.49% | ↗ |
| 4 | 2025 | Chrystal Jensen Chief Legal Officer, General Counsel and Secretary | 487.1K | — | 866.8K | — | 265.7K | 2.8K | 1.62M | 53.43% | ↗ |
| 5 | 2025 | Richard Benjamin Chief Medical Officer | 508.7K | — | 713.8K | — | 276.9K | 7.1K | 1.51M | 47.38% | ↗ |
| 6 | 2024 | William M. Greenman President and Chief Executive Officer | 770.0K | 110.5K | 2.09M | — | — | 2.3K | 2.98M | 70.33% | ↗ |
| 7 | 2024 | Vivek Jayaraman Chief Operating Officer | 548.4K | 60.3K | 872.0K | — | — | 3.1K | 1.48M | 58.77% | ↗ |
| 8 | 2024 | Kevin D. Green Chief Financial Officer | 488.1K | 53.7K | 725.9K | — | — | 1.2K | 1.27M | 57.21% | ↗ |
| 9 | 2024 | Kevin D. Green Vice President, Finance and Chief Financial Officer | 488.1K | 53.7K | 725.9K | — | — | 1.2K | 1.27M | 57.21% | ↗ |
| 10 | 2024 | Richard Benjamin Chief Medical Officer | 493.1K | 44.4K | 588.6K | — | — | 3.6K | 1.13M | 52.11% | ↗ |
| 11 | 2024 | Chrystal Jensen Chief Legal Officer, General Counsel and Secretary | 468.5K | 46.4K | 588.6K | — | — | 1.2K | 1.10M | 53.28% | ↗ |
| 12 | 2023 | William M. Greenman President and Chief Executive Officer | 763.8K | — | 2.62M | — | 269.5K | 2.4K | 3.66M | 71.71% | ↗ |
| 13 | 2023 | Vivek Jayaraman Chief Operating Officer | 544.0K | — | 1.09M | — | 150.8K | 1.9K | 1.79M | 61.09% | ↗ |
| 14 | 2023 | Kevin D. Green Vice President, Finance and Chief Financial Officer | 484.2K | — | 854.0K | — | 122.0K | 1.3K | 1.46M | 58.43% | ↗ |
| 15 | 2023 | Richard Benjamin Chief Medical Officer | 489.1K | — | 738.6K | — | 110.9K | 3.6K | 1.34M | 55.03% | ↗ |
| 16 | 2023 | Chrystal Jensen Chief Legal Officer, General Counsel and Secretary | 464.8K | — | 738.6K | — | 105.4K | 1.3K | 1.31M | 56.38% | ↗ |
| 17 | 2023 | Chrystal Jensen Chief Legal Officer, General Counsel and Secretary | 464.8K | — | 738.6K | — | 105.4K | 1.3K | 1.31M | 56.38% | ↗ |
| 18 | 2022 | William M. Greenman President and Chief Executive Officer | 732.1K | — | 2.51M | 1.43M | 595.7K | 2.4K | 5.26M | 74.73% | ↗ |
| 19 | 2022 | Vivek Jayaraman Chief Operating Officer | 522.1K | — | 1.04M | 590.8K | 333.5K | 6.1K | 2.49M | 65.39% | ↗ |
| 20 | 2022 | Kevin D. Green Vice President, Finance and Chief Financial Officer | 464.7K | — | 806.4K | 459.5K | 269.9K | 13.9K | 2.01M | 62.84% | ↗ |
| 21 | 2022 | Richard Benjamin Chief Medical Officer | 470.8K | — | 604.8K | 344.7K | 245.4K | 3.6K | 1.67M | 56.88% | ↗ |
| 22 | 2022 | Chrystal Jensen Chief Legal Officer, General Counsel and Secretary | 446.9K | — | 604.8K | 344.7K | 233.1K | 12.1K | 1.64M | 57.84% | ↗ |
| 23 | 2022 | Chrystal Jensen Chief Legal Officer, General Counsel and Secretary | 446.9K | — | 604.8K | 344.7K | 233.1K | 12.1K | 1.64M | 57.84% | ↗ |
| 24 | 2021 | William M. Greenman President and Chief Executive Officer | 696.4K | — | 2.53M | 1.41M | 547.6K | 2.4K | 5.18M | 75.95% | ↗ |
| 25 | 2021 | Vivek Jayaraman Chief Operating Officer | 497.2K | — | 978.0K | 555.1K | 346.5K | 1.6K | 2.38M | 64.46% | ↗ |
| 26 | 2021 | Kevin D. Green Vice President, Finance and Chief Financial Officer | 443.4K | — | 847.6K | 481.1K | 253.4K | 1.3K | 2.03M | 65.55% | ↗ |
| 27 | 2021 | Richard Benjamin Chief Medical Officer | 455.3K | — | 652.0K | 370.1K | 259.7K | 3.6K | 1.74M | 58.72% | ↗ |
| 28 | 2021 | Laurence M. Corash Chief Scientific Officer | 456.5K | — | 652.0K | 370.1K | 230.1K | 11.2K | 1.72M | 59.43% | ↗ |
| 29 | 2020 | William M. Greenman President and Chief Executive Officer | 669.8K | — | 1.61M | 1.73M | 504.6K | 1.3K | 4.52M | 73.99% | ↗ |
| 30 | 2020 | Vivek Jayaraman Chief Operating Officer | 469.2K | — | 663.7K | 711.4K | 269.0K | 1.6K | 2.11M | 65.02% | ↗ |
| 31 | 2020 | Laurence M. Corash Chief Scientific Officer | 445.0K | — | 352.2K | 377.6K | 225.8K | 11.5K | 1.41M | 51.68% | ↗ |
| 32 | 2020 | Richard Benjamin Chief Medical Officer | 441.6K | — | 352.2K | 377.6K | 236.4K | 3.6K | 1.41M | 51.71% | ↗ |
| 33 | 2020 | Kevin D. Green Vice President, Finance and Chief Financial Officer | 425.5K | — | 352.2K | 377.6K | 228.5K | 860.00 | 1.38M | 52.71% | ↗ |
| 34 | 2019 | William M. Greenman President and Chief Executive Officer | 645.0K | — | 2.16M | — | 462.6K | 1.3K | 3.27M | 66.09% | ↗ |
| 35 | 2019 | Vivek Jayaraman Chief Operating Officer | 431.4K | — | 641.3K | — | 238.1K | 1.6K | 1.31M | 48.87% | ↗ |
| 36 | 2019 | Laurence M. Corash Chief Scientific Officer | 439.0K | — | 641.3K | — | 195.8K | 11.6K | 1.29M | 49.80% | ↗ |
| 37 | 2019 | Richard Benjamin Chief Medical Officer | 427.3K | — | 641.3K | — | 190.6K | 2.4K | 1.26M | 50.83% | ↗ |
| 38 | 2019 | Kevin D. Green Vice President, Finance and Chief Financial Officer | 406.1K | — | 641.3K | — | 201.7K | 894.00 | 1.25M | 51.30% | ↗ |
| 39 | 2018 | William M. Greenman President and Chief Executive Officer | 616.7K | — | 928.8K | 990.3K | 446.4K | 1.2K | 2.98M | 64.33% | ↗ |
| 40 | 2018 | Vivek Jayaraman Chief Commercial Officer | 412.4K | — | 205.2K | 218.8K | 256.5K | 990.00 | 1.09M | 38.76% | ↗ |
| 41 | 2018 | Vivek Jayaraman Chief Operating Officer | 412.4K | — | 205.2K | 218.8K | 256.5K | 990.00 | 1.09M | 38.76% | ↗ |
| 42 | 2018 | Laurence M. Corash Chief Scientific Officer | 425.9K | — | 205.2K | — | 178.6K | 11.7K | 1.04M | 19.73% | ↗ |
| 43 | 2018 | Kevin D. Green Vice President, Finance and Chief Financial Officer | 386.8K | — | 205.2K | 218.8K | 210.7K | 810.00 | 1.02M | 41.48% | ↗ |
| 44 | 2018 | Richard Benjamin Chief Medical Officer | 412.8K | — | 205.2K | — | 174.1K | 2.3K | 1.01M | 20.25% | ↗ |
| 45 | 2017 | William M. Greenman President and Chief Executive Officer | 596.7K | — | 365.3K | 899.3K | 261.0K | 1.2K | 2.12M | 59.55% | ↗ |
| 46 | 2017 | Laurence M. Corash Chief Scientific Officer | 421.0K | — | 97.4K | 224.8K | 116.4K | 11.7K | 871.3K | 36.98% | ↗ |
| 47 | 2017 | Richard Benjamin Chief Medical Officer | 398.6K | — | 97.4K | 224.8K | 116.3K | 2.3K | 839.5K | 38.39% | ↗ |
| 48 | 2017 | Kevin D. Green Vice President, Finance and Chief Financial Officer | 368.3K | — | 97.4K | 224.8K | 123.8K | 810.00 | 815.2K | 39.53% | ↗ |
| 49 | 2017 | Chrystal Menard | 371.8K | — | 97.4K | 224.8K | 109.5K | 810.00 | 804.3K | 40.06% | ↗ |
| 50 | 2017 | Vivek Jayaraman Chief Operating Officer | 403.3K | — | 48.7K | 112.4K | 105.4K | 990.00 | 670.9K | 24.02% | ↗ |
| 51 | 2017 | Vivek Jayaraman Chief Commercial Officer | 403.3K | — | 48.7K | 112.4K | 105.4K | 990.00 | 670.9K | 24.02% | ↗ |
| 52 | 2016 | William M. Greenman President and Chief Executive Officer | 576.7K | — | 341.6K | 776.6K | 307.1K | 1.2K | 2.00M | 55.82% | ↗ |
| 53 | 2016 | Vivek Jayaraman Chief Commercial Officer | 137.6K | 53.3K | 477.0K | 770.7K | — | 180.00 | 1.44M | 86.72% | ↗ |
| 54 | 2016 | Vivek Jayaraman Chief Commercial Officer | 137.6K | 53.3K | 477.0K | 770.7K | — | 180.00 | 1.44M | 86.72% | ↗ |
| 55 | 2016 | Laurence M. Corash Chief Scientific Officer | 413.4K | — | 91.1K | 221.9K | 171.2K | 11.1K | 908.7K | 34.44% | ↗ |
| 56 | 2016 | Kevin D. Green Vice President, Finance and Chief Financial Officer | 351.3K | — | 91.1K | 221.9K | 124.8K | 776.00 | 789.9K | 39.62% | ↗ |
| 57 | 2016 | Richard Benjamin Chief Medical Officer | 384.8K | — | 45.5K | 110.9K | 136.2K | 2.2K | 679.6K | 23.03% | ↗ |
| 58 | 2015 | William M. Greenman President and Chief Executive Officer | 554.2K | — | — | 1.24M | 268.8K | 810.00 | 2.06M | 60.06% | ↗ |
| 59 | 2015 | Richard Benjamin Chief Medical Officer | 178.6K | — | — | 920.4K | 60.8K | 125.0K | 1.28M | 71.64% | ↗ |
| 60 | 2015 | Richard Benjamin Chief Medical Officer | 178.6K | — | — | 920.4K | 60.8K | 125.0K | 1.28M | 71.64% | ↗ |
| 61 | 2015 | Laurence M. Corash Chief Scientific Officer | 409.6K | — | — | 527.8K | 118.1K | 11.4K | 1.07M | 49.47% | ↗ |
| 62 | 2015 | Carol M. Moore Senior Vice President, Regulatory Affairs and Quality | 334.6K | — | — | 408.9K | 96.8K | 6.9K | 847.1K | 48.27% | ↗ |
| 63 | 2015 | Kevin D. Green Vice President, Finance and Chief Financial Officer | 335.6K | — | — | 371.7K | 125.1K | 7.1K | 839.5K | 44.28% | ↗ |
| 64 | 2014 | William M. Greenman President and Chief Executive Officer | 520.8K | — | — | 1.18M | 244.1K | 810.00 | 1.94M | 60.56% | ↗ |
| 65 | 2014 | Laurence M. Corash Chief Scientific Officer | 406.5K | 20.0K | — | — | 134.6K | 11.7K | 1.06M | 0.00% | ↗ |
| 66 | 2014 | Laurence M. Corash Senior Vice President, Chief Medical and Chief Scientific Officer | 406.5K | 20.0K | — | 488.4K | 134.6K | 11.7K | 1.06M | 46.02% | ↗ |
| 67 | 2014 | Carol M. Moore Senior Vice President, Regulatory Affairs, Quality and Clinical | 324.8K | 50.8K | — | 488.4K | 114.2K | 3.6K | 981.7K | 49.75% | ↗ |
| 68 | 2014 | Carol M. Moore Senior Vice President, Regulatory Affairs and Quality | 324.8K | 50.8K | — | 488.4K | 114.2K | 3.6K | 981.7K | 49.75% | ↗ |
| 69 | 2014 | Caspar Hogeboom President, Cerus Europe and EEMEA | 281.6K | — | — | 490.0K | 53.8K | 75.3K | 900.6K | 54.41% | ↗ |
| 70 | 2014 | Kevin D. Green Vice President, Finance and Chief Financial Officer | 307.6K | 790.00 | — | 452.2K | 54.8K | 840.00 | 816.2K | 55.40% | ↗ |
| 71 | 2013 | William M. Greenman President and Chief Executive Officer | 495.8K | — | — | 771.1K | 183.0K | 810.00 | 1.45M | 53.15% | ↗ |
| 72 | 2013 | Laurence M. Corash, Senior Vice President, Chief Medical and Chief Scientific Officer | 398.2K | — | — | 336.1K | 90.0K | 7.3K | 831.7K | 40.41% | ↗ |
| 73 | 2013 | Laurence M. Corash Chief Scientific Officer | 398.2K | — | — | — | 90.0K | 7.3K | 831.7K | 0.00% | ↗ |
| 74 | 2013 | Laurence M. Corash Senior Vice President, Chief Medical and Chief Scientific Officer | 398.2K | — | — | 336.1K | 90.0K | 7.3K | 831.7K | 40.41% | ↗ |
| 75 | 2013 | Caspar Högeboom President, Cerus Europe | 304.4K | — | — | 347.0K | 62.0K | 84.0K | 797.4K | 43.52% | ↗ |
| 76 | 2013 | Caspar Hogeboom President, Cerus Europe and EEMEA | 304.4K | — | — | 347.0K | 62.0K | 84.0K | 797.4K | 43.52% | ↗ |
| 77 | 2013 | Carol M. Moore Senior Vice President, Regulatory Affairs, Quality and Clinical | 315.4K | — | — | 336.1K | 71.0K | 4.0K | 726.5K | 46.27% | ↗ |
| 78 | 2013 | Carol M. Moore Senior Vice President, Regulatory Affairs and Quality | 315.4K | — | — | 336.1K | 71.0K | 4.0K | 726.5K | 46.27% | ↗ |
| 79 | 2013 | Carol M. Moore Senior Vice President, Regulatory Affairs, Quality and Clinical | 315.4K | — | — | 336.1K | 71.0K | 4.0K | 726.5K | 46.27% | ↗ |
| 80 | 2013 | Kevin D. Green Vice President, Finance and Chief Financial Officer | 277.0K | — | — | 197.7K | 65.0K | 990.00 | 540.7K | 36.57% | ↗ |
| 81 | 2012 | William M. Greenman President and Chief Executive Officer | 465.0K | — | — | 839.9K | 259.9K | 810.00 | 1.57M | 53.65% | ↗ |
| 82 | 2012 | Laurence M. Corash Senior Vice President, Chief Medical and Chief Scientific Officer | 388.2K | — | — | 287.3K | 112.0K | 7.5K | 795.0K | 36.14% | ↗ |
| 83 | 2012 | Laurence M. Corash, Senior Vice President, Chief Medical and Chief Scientific Officer | 388.2K | — | — | 287.3K | 112.0K | 7.5K | 795.0K | 36.14% | ↗ |
| 84 | 2012 | Caspar Högeboom President, Cerus Europe | 284.8K | — | — | 239.1K | 106.0K | 77.9K | 707.7K | 33.78% | ↗ |
| 85 | 2012 | Caspar Hogeboom President, Cerus Europe and EEMEA | 284.8K | — | — | 239.1K | 106.0K | 77.9K | 707.7K | 33.78% | ↗ |
| 86 | 2012 | Caspar Hogeboom President, Cerus Europe | 284.8K | — | — | 239.1K | 106.0K | 77.9K | 707.7K | 33.78% | ↗ |
| 87 | 2012 | Howard G. Ervin Vice President, Legal Affairs and former Chief Legal Officer | 325.7K | — | — | 198.9K | 104.5K | 6.9K | 636.0K | 31.28% | ↗ |
| 88 | 2012 | Kevin D. Green Vice President, Finance and Chief Financial Officer | 260.2K | — | — | 210.0K | 92.5K | 987.00 | 563.6K | 37.25% | ↗ |
| 89 | 2011 | William M. Greenman President and Chief Executive Officer | 386.1K | — | — | 1.03M | 181.8K | 810.00 | 1.59M | 64.33% | ↗ |
| 90 | 2011 | Laurence M. Corash, Senior Vice President, Chief Medical and Chief Scientific Officer | 378.1K | — | — | 161.8K | 96.8K | 7.3K | 644.0K | 25.13% | ↗ |
| 91 | 2011 | Laurence M. Corash, Senior Vice President, Chief Medical Officer | 378.1K | — | — | 161.8K | 96.8K | 7.3K | 644.0K | 25.13% | ↗ |
| 92 | 2011 | Caspar Hogeboom President, Cerus Europe and EEMEA | 286.8K | — | — | 166.7K | 73.3K | 83.9K | 610.7K | 27.29% | ↗ |
| 93 | 2011 | Caspar Hogeboom President, Cerus Europe | 285.4K | — | — | 166.7K | 73.3K | 84.7K | 610.1K | 27.32% | ↗ |
| 94 | 2011 | Caspar Högeboom President, Cerus Europe | 285.4K | — | — | — | 73.3K | 84.7K | 610.1K | 0.00% | ↗ |
| 95 | 2011 | Howard G. Ervin Vice President, Legal Affairs and former Chief Legal Officer | 316.7K | — | — | 105.8K | 81.2K | 3.6K | 507.3K | 20.86% | ↗ |
| 96 | 2011 | Howard G. Ervin Vice President, Legal Affairs and former Chief Legal Officer | 316.7K | — | — | 105.8K | 81.2K | 3.6K | 507.3K | 20.86% | ↗ |
| 97 | 2011 | Kevin D. Green Vice President, Finance and Chief Financial Officer | 238.3K | — | — | 99.7K | 61.8K | 962.00 | 400.8K | 24.87% | ↗ |
| 98 | 2011 | Kevin D. Green Vice President, Finance and Chief Accounting Officer | 238.3K | — | — | 99.7K | 61.8K | 962.00 | 400.8K | 24.87% | ↗ |
| 99 | 2011 | Claes Glassell Former President and Chief Executive Officer | 206.7K | — | — | 132.00 | — | 10.3K | 217.1K | 0.06% | ↗ |
| 100 | 2010 | Claes Glassell Former President and Chief Executive Officer | 490.0K | — | 44.1K | 413.0K | 194.0K | 2.3K | 1.14M | 39.97% | ↗ |
| 101 | 2010 | Laurence M. Corash, M.D. Senior Vice President and Chief Medical Officer | 353.1K | — | 140.0K | 154.9K | 86.6K | 6.8K | 741.5K | 39.77% | ↗ |
| 102 | 2010 | Laurence M. Corash, Senior Vice President, Chief Medical and Chief Scientific Officer | 353.1K | — | 140.0K | 154.9K | 86.6K | 6.8K | 741.5K | 39.77% | ↗ |
| 103 | 2010 | Laurence M. Corash, Senior Vice President, Chief Medical Officer | 353.1K | — | 140.0K | 154.9K | 86.6K | 6.8K | 741.5K | 39.77% | ↗ |
| 104 | 2010 | William M. Greenman President and Chief Executive Officer | 312.0K | — | 14.0K | 206.5K | 72.1K | 540.00 | 605.1K | 36.44% | ↗ |
| 105 | 2010 | Howard G. Ervin Vice President, Legal Affairs and former Chief Legal Officer | 311.5K | — | 14.0K | 92.9K | 72.0K | 3.6K | 494.0K | 21.65% | ↗ |
| 106 | 2010 | Kevin D. Green Vice President, Finance and Chief Financial Officer | 220.0K | — | 6.9K | 103.2K | 50.8K | 421.00 | 381.4K | 28.89% | ↗ |
| 107 | 2010 | Kevin D. Green Vice President, Finance and Chief Accounting Officer | 220.0K | — | 6.9K | 103.2K | 50.8K | 421.00 | 381.4K | 28.89% | ↗ |
| 108 | 2009 | Claes Glassell President and Chief Executive Officer | 490.0K | — | — | 261.9K | 102.9K | 2.3K | 857.1K | 30.55% | ↗ |
| 109 | 2009 | Claes Glassell Former President and Chief Executive Officer | 490.0K | — | — | 261.9K | 102.9K | 2.3K | 857.1K | 30.55% | ↗ |
| 110 | 2009 | William M. Greenman President and Chief Executive Officer | 312.0K | — | — | 143.7K | 32.8K | 540.00 | 489.0K | 29.39% | ↗ |
| 111 | 2009 | William M. Greenman Senior Vice President, Business Development and Marketing | 312.0K | — | — | 143.7K | 32.8K | 540.00 | 489.0K | 29.39% | ↗ |
| 112 | 2009 | Laurence M. Corash, M.D. Senior Vice President and Chief Medical Officer | 287.5K | — | — | 92.8K | 25.6K | 6.7K | 412.6K | 22.48% | ↗ |
| 113 | 2009 | Laurence M. Corash, Senior Vice President, Chief Medical Officer | 287.5K | — | — | 92.8K | 25.6K | 6.7K | 412.6K | 22.48% | ↗ |
| 114 | 2009 | Kevin D. Green Vice President, Finance and Chief Accounting Officer | 220.0K | — | — | 87.8K | 16.2K | 339.00 | 324.3K | 27.07% | ↗ |
| 115 | 2008 | Claes Glassell President and Chief Executive Officer | 487.0K | — | 99.0K | 298.6K | — | 2.3K | 886.9K | 44.83% | ↗ |
| 116 | 2008 | William M. Greenman President, Cerus Europe | 310.0K | — | 19.7K | 136.0K | — | 65.2K | 530.9K | 29.32% | ↗ |
| 117 | 2008 | William M. Greenman Senior Vice President, Business Development and Marketing | 310.0K | — | 31.5K | 119.4K | — | 65.2K | 526.1K | 28.69% | ↗ |
| 118 | 2008 | Laurence M. Corash, M.D. Senior Vice President and Chief Medical Officer | 373.2K | — | 38.2K | 104.5K | — | 3.6K | 519.5K | 27.48% | ↗ |
| 119 | 2008 | Howard G. Ervin Vice President, Legal Affairs | 309.5K | — | 20.9K | 98.5K | — | 3.6K | 432.4K | 27.60% | ↗ |
| 120 | 2008 | William J. Dawson Vice President, Finance and Chief Financial Officer | 291.4K | — | 17.9K | 99.8K | — | 1.2K | 410.4K | 28.69% | ↗ |
| 121 | 2007 | Claes Glassell President and Chief Executive Officer | 468.4K | — | 31.6K | 245.7K | 231.0K | 2.3K | 979.0K | 28.32% | ↗ |
| 122 | 2007 | Laurence M. Corash, M.D. Senior Vice President and Chief Medical Officer | 363.0K | — | 12.5K | 100.6K | 89.2K | 3.6K | 568.8K | 19.88% | ↗ |
| 123 | 2007 | William M. Greenman President, Cerus Europe | 293.6K | — | 9.2K | 140.7K | 73.5K | 45.6K | 562.5K | 26.64% | ↗ |
| 124 | 2007 | Howard G. Ervin Vice President, Legal Affairs | 297.4K | — | 10.0K | 95.1K | 76.0K | 3.6K | 482.1K | 21.80% | ↗ |
| 125 | 2007 | Howard G. Ervin Vice President, Legal Affairs | 297.4K | — | 10.0K | 95.1K | 76.0K | 3.6K | 482.1K | 21.80% | ↗ |
| 126 | 2007 | David N. Cook, Ph.D. Senior Corporate Vice President | 289.8K | — | 11.0K | 111.9K | — | 32.3K | 445.0K | 27.63% | ↗ |
| 127 | 2007 | William J. Dawson Vice President, Finance and Chief Financial Officer | 280.0K | — | 9.4K | 94.1K | 59.2K | 1.2K | 444.0K | 23.32% | ↗ |
| 128 | 2006 | Claes Glassell President and Chief Executive Officer | 447.9K | — | 36.6K | 334.5K | 221.2K | 2.3K | 1.04M | 35.59% | ↗ |
| 129 | 2006 | Claes Glassell President and Chief Executive Officer | 447.9K | — | 36.6K | 334.5K | 221.2K | 2.3K | 1.04M | 35.59% | ↗ |
| 130 | 2006 | Laurence M. Corash, M.D. Vice President and Chief Medical Officer | 355.8K | — | 13.6K | 141.9K | 87.5K | 11.9K | 610.6K | 25.46% | ↗ |
| 131 | 2006 | Laurence M. Corash, M.D. Senior Vice President and Chief Medical Officer | 355.8K | — | 13.6K | 141.9K | 87.5K | 11.9K | 610.6K | 25.46% | ↗ |
| 132 | 2006 | David N. Cook, Ph.D. Senior Corporate Vice President | 312.5K | — | 13.9K | 164.6K | 77.2K | 8.1K | 576.2K | 30.97% | ↗ |
| 133 | 2006 | David N. Cook, Ph.D. Vice President, Research and Development | 312.5K | — | 13.9K | 164.6K | 77.2K | 8.1K | 576.2K | 30.97% | ↗ |
| 134 | 2006 | William M. Greenman President, Cerus Europe | 258.0K | — | 11.1K | 166.1K | 64.1K | 544.00 | 499.9K | 35.45% | ↗ |
| 135 | 2006 | William M. Greenman President, Cerus Europe | 258.0K | — | 11.1K | 166.1K | 64.1K | 544.00 | 499.9K | 35.45% | ↗ |
| 136 | 2006 | William J. Dawson Vice President, Finance and Chief Financial Officer | 267.7K | — | 10.6K | 107.7K | 66.1K | 1.3K | 453.4K | 26.09% | ↗ |
| 137 | 2006 | William J. Dawson Vice President, Finance and Chief Financial Officer | 267.7K | — | 10.6K | 107.7K | 66.1K | 1.3K | 453.4K | 26.09% | ↗ |
| 138 | 2005 | Claes Glassell President and Chief Executive Officer | 427.5K | 305.9K | 109.7K | 75.0K | — | 1.2K | 844.2K | 21.87% | ↗ |
| 139 | 2005 | Laurence M. Corash Vice President and Chief Medical Officer | 354.4K | 94.9K | 40.7K | 40.0K | — | 3.6K | 493.6K | 16.34% | ↗ |
| 140 | 2005 | David N. Cook Vice President, Research and Development | 302.1K | 97.1K | 41.6K | 50.0K | — | 810.00 | 441.6K | 20.75% | ↗ |
| 141 | 2005 | Howard G. Ervin Vice President, Legal Affairs | 271.8K | 128.8K | 33.8K | 40.0K | — | 2.3K | 436.7K | 16.89% | ↗ |
| 142 | 2005 | William J. Dawson Vice President, Finance and Chief Financial Officer | 255.8K | 94.2K | 31.8K | 40.0K | — | 1.2K | 383.1K | 18.74% | ↗ |
| 143 | 2004 | Laurence M. Corash Vice President and Chief Medical Officer | 344.3K | 146.7K | 38.9K | 125.1K | — | 3.9K | 533.7K | 30.72% | ↗ |
| 144 | 2004 | Laurence M. Corash Vice President, Medical Affairs and Chief Medical Officer | 344.3K | 146.7K | 38.9K | 125.1K | — | 3.9K | 533.7K | 30.72% | ↗ |
| 145 | 2004 | Stephen T. Isaacs President and Chief Executive Officer | 147.9K | — | 53.7K | — | — | 326.9K | 528.6K | 10.17% | ↗ |
| 146 | 2004 | Claes Glassell President and Chief Executive Officer | 273.7K | 175.0K | — | 600.0K | — | 828.00 | 449.5K | 133.48% | ↗ |
| 147 | 2004 | David N. Cook Vice President, Research and Development | 282.6K | 121.8K | 38.9K | 125.0K | — | 844.00 | 444.1K | 36.90% | ↗ |
| 148 | 2004 | Howard G. Ervin Vice President, Legal Affairs | 270.7K | 88.3K | 35.5K | 100.1K | — | 2.4K | 396.9K | 34.15% | ↗ |
| 149 | 2004 | Gregory W. Schafer Vice President, Finance and Chief Financial Officer | 165.4K | — | — | 75.00 | — | 180.3K | 345.7K | 0.02% | ↗ |
| 150 | 2004 | William J. Dawson Vice President, Finance and Chief Financial Officer | 98.6K | 34.6K | — | 150.0K | — | 518.00 | 133.7K | 112.18% | ↗ |
| 151 | 2003 | Stephen T. Isaacs President and Chief Executive Officer | 415.0K | — | — | 85.0K | — | 1.2K | 416.2K | 20.42% | ↗ |
| 152 | 2003 | Stephen T. Isaacs President and Chief Executive Officer | 415.0K | — | — | 85.0K | — | 1.2K | 416.2K | 20.42% | ↗ |
| 153 | 2003 | Laurence M. Corash Vice President, Medical Affairs and Chief Medical Officer | 335.4K | 49.6K | — | 58.3K | — | 2.4K | 387.4K | 15.06% | ↗ |
| 154 | 2003 | Laurence M. Corash Vice President and Chief Medical Officer | 335.4K | 49.6K | — | 58.3K | — | 2.4K | 387.4K | 15.06% | ↗ |
| 155 | 2003 | Laurence M. Corash Vice President, Medical Affairs | 335.4K | 49.6K | — | 58.3K | — | 2.4K | 387.4K | 15.06% | ↗ |
| 156 | 2003 | David N. Cook Vice President, Research and Development | 262.4K | 41.8K | — | 83.2K | — | 822.00 | 305.0K | 27.27% | ↗ |
| 157 | 2003 | David N. Cook Vice President, Research and Development | 262.4K | 41.8K | — | 83.2K | — | 822.00 | 305.0K | 27.27% | ↗ |
| 158 | 2003 | Howard G. Ervin Vice President, Legal Affairs | 259.0K | 30.6K | — | 41.0K | — | 2.4K | 292.0K | 14.04% | ↗ |
| 159 | 2003 | Howard G. Ervin Vice President, Legal Affairs | 259.0K | 30.6K | — | — | — | 2.4K | 292.0K | 0.00% | ↗ |
| 160 | 2003 | Gregory W. Schafer Vice President, Finance and Chief Financial Officer | 243.0K | 33.1K | — | 41.3K | — | 473.00 | 276.6K | 14.92% | ↗ |
| 161 | 2003 | Gregory W. Schafer Vice President, Finance and Chief Financial Officer | 243.0K | 33.1K | — | 41.3K | — | 473.00 | 276.6K | 14.92% | ↗ |
| 162 | 2003 | William J. Dawson Vice President, Finance and Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 163 | 2003 | Claes Glassell President and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 164 | 2002 | Stephen T. Isaacs President and Chief Executive Officer | 415.0K | 95.2K | — | 95.1K | — | 1.2K | 511.5K | 18.59% | ↗ |
| 165 | 2002 | Stephen T. Isaacs President and Chief Executive Officer | 415.0K | 95.2K | — | 95.1K | — | 1.2K | 511.5K | 18.59% | ↗ |
| 166 | 2002 | Laurence M. Corash Vice President, Medical Affairs | 319.2K | 65.9K | — | 59.2K | — | 2.5K | 387.6K | 15.26% | ↗ |
| 167 | 2002 | Laurence M. Corash Vice President, Medical Affairs and Chief Medical Officer | 319.2K | 65.9K | — | 59.2K | — | 2.5K | 387.6K | 15.26% | ↗ |
| 168 | 2002 | Howard G. Ervin Vice President, Legal Affairs | 253.1K | 43.6K | — | 35.7K | — | 2.5K | 299.2K | 11.94% | ↗ |
| 169 | 2002 | Howard G. Ervin Vice President, Legal Affairs | 253.1K | 43.6K | — | — | — | 2.5K | 299.2K | 0.00% | ↗ |
| 170 | 2002 | Gregory W. Schafer Vice President, Finance and Chief Financial Officer | 240.0K | 45.1K | — | 43.4K | — | 454.00 | 285.6K | 15.19% | ↗ |
| 171 | 2002 | Gregory W. Schafer Vice President, Finance and Chief Financial Officer | 240.0K | 45.1K | — | 43.4K | — | 454.00 | 285.6K | 15.19% | ↗ |
| 172 | 2002 | David N. Cook Vice President, Research and Development | 218.8K | 43.6K | — | 43.3K | — | 465.00 | 262.8K | 16.49% | ↗ |
| 173 | 2002 | David N. Cook Vice President, Research and Development | 218.8K | 43.6K | — | 43.3K | — | 465.00 | 262.8K | 16.49% | ↗ |
| 174 | 2002 | Claes Glassell President and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 175 | 2002 | William J. Dawson Vice President, Finance and Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 176 | 2001 | Stephen T. Isaacs President and Chief Executive Officer | 380.0K | 162.3K | — | 100.1K | — | 1.2K | 543.5K | 18.41% | ↗ |
| 177 | 2001 | Laurence M. Corash Vice President, Medical Affairs | 304.0K | 114.6K | — | 70.1K | — | 2.2K | 420.8K | 16.67% | ↗ |
| 178 | 2001 | John E. Hearst Vice President, New Science Opportunities | 240.0K | 87.2K | — | 40.1K | — | 6.4K | 333.6K | 12.00% | ↗ |
| 179 | 2001 | Howard G. Ervin Vice President, Legal Affairs | 241.0K | 72.3K | — | 17.5K | — | 1.1K | 314.5K | 5.56% | ↗ |
| 180 | 2001 | Gregory W. Schafer Vice President, Finance and Chief Financial Officer | 213.0K | 60.2K | — | 25.0K | — | 382.00 | 273.6K | 9.15% | ↗ |
| 181 | 2001 | David N. Cook Vice President, Research and Development | 165.0K | 35.2K | — | 55.0K | — | 130.00 | 200.4K | 27.45% | ↗ |
| 182 | 2000 | Stephen T. Isaacs President and Chief Executive Officer | 325.0K | 94.5K | — | 40.0K | — | 966.00 | 420.4K | 9.51% | ↗ |
| 183 | 2000 | Laurence M. Corash Vice President, Medical Affairs | 278.3K | 60.3K | — | 32.5K | — | 1.8K | 340.3K | 9.55% | ↗ |
| 184 | 2000 | Howard G. Ervin Vice President, Legal Affairs | 220.4K | 43.1K | — | 10.0K | — | 966.00 | 264.4K | 3.78% | ↗ |
| 185 | 2000 | John E. Hearst Vice President, New Science Opportunities | 220.5K | 36.8K | — | 20.0K | — | 4.5K | 261.8K | 7.64% | ↗ |
| 186 | 2000 | Gregory W. Schafer Vice President, Finance and Chief Financial Officer | 165.0K | 31.0K | — | 45.0K | — | 292.00 | 196.3K | 22.92% | ↗ |
| 187 | 1999 | Stephen T. Isaacs President and Chief Executive Officer | 300.0K | 91.5K | — | — | — | 1.8K | 393.3K | 0.00% | ↗ |
| 188 | 1999 | Laurence M. Corash Vice President, Medical Affairs | 265.0K | 53.5K | — | — | — | 1.6K | 320.0K | 0.00% | ↗ |
| 189 | 1999 | John E. Hearst Vice President, New Science Opportunities | 210.0K | 20.1K | — | — | — | 4.6K | 234.7K | 0.00% | ↗ |
| 190 | 1999 | Gregory W. Schafer Vice President, Finance and Chief Financial Officer | 125.8K | 23.7K | — | 25.0K | — | 151.00 | 149.6K | 16.71% | ↗ |
| 191 | 1999 | Howard G. Ervin Vice President, Legal Affairs | 110.3K | 12.3K | — | 75.0K | — | 345.00 | 123.0K | 60.98% | ↗ |
| 192 | 1998 | Stephen T. Isaacs President and Chief Executive Officer | 280.0K | 80.0K | — | 40.0K | — | 1.1K | 361.1K | 11.08% | ↗ |
| 193 | 1998 | Laurence M. Corash Vice President, Medical Affairs | 250.0K | 40.0K | — | 40.0K | — | 1.4K | 291.4K | 13.72% | ↗ |
| 194 | 1998 | John E. Hearst Vice President, New Science Opportunities | 176.2K | 25.0K | — | 25.0K | — | 3.8K | 204.9K | 12.20% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| William Greenman | President, Chief Executive Officer & Chairman | 2M | male |
| Vivek K. Jayaraman | Chief Operating Officer | 964.2K | male |
| Kevin D. Green | Vice President of Finance & Chief Financial Officer | 831.6K | male |
| Richard J. Benjamin | Chief Medical Officer | 792.7K | — |
| Chrystal Jensen | Chief Legal Officer, General Counsel & Secretary | 755.5K | female |
| Laurence Corash | Co-Founder & Chief Scientific Officer | 697.8K | — |
| Carol Moore | Senior Vice President of Regulatory Affairs, Quality & Clinical | 438.2K | female |
| Timothy J. Lee | Head of Investor Relation | — | male |
| Nina Mufti | Senior Vice President of Research & Development | — | — |
| Lainie Corten | Vice President of Global Marketing | — | — |
ESG Rating
ESG Score History MEDICAL - DEVICES
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CERS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
